MICHAEL H. MENGEL, MD

Chair, Department of Laboratory Medicine and Pathology, University of AlbertaProfessor, Department of Laboratory Medicine and Pathology, University of Alberta

Business AddressUniversity of Alberta

3-126 Li Ka Shing Health Research innovation CenterT6G 2S2 Edmonton, Alberta, Canada

Telephone: 1-780-492-5943Email: mmengel@ualberta.ca

CitizenshipGerman Citizen

Permanent Resident of Canada

Job Description40% Research, 25% Clinical, 25% Administration, 10% Teaching (Workplace)

CONTENTS OF CURRICULUM VITAE

EDUCATION...............................................................................................................................................2

APPOINTMENTS & LEADERSHIP HIGHLIGHTS.............................................................................................3

AWARDS...................................................................................................................................................7

PUBLICATIONS & INTELLECTUAL PROPERTY...............................................................................................8

PRESENTATIONS & SCIENTIFIC MEETINGS................................................................................................19

RESEARCH FUNDING................................................................................................................................24

TEACHING & EDUCATIONAL ACTIVITIES...................................................................................................26

NON ACADEMIC ACTIVITIES.....................................................................................................................30

M Mengel: CV

EDUCATION

Degrees1995: Doctor of Medicine, summa cum laudeSemmelweis University, Budapest, Hungary

2002: Doctorate (Dr.med)Institute of Pathology, Hannover Medical School, Hannover, GermanyThesis title: “Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labeling index in a large multi-centre trial”

2006: “Habilitation” Institute of Pathology, Hannover Medical School, Hannover, GermanyThesis title: “Injury and regeneration mechanisms of chronic allograft nephropathy”

Residency & Fellowships1995-2004: Intern, Resident and Senior Fellow for PathologyInstitute of Pathology, Hannover Medical School, Hannover, Germany

Dec 1998 - Mar 1999: Fellowship in nephropathologyGerman Cancer Research Centre (DKFZ), Heidelberg, GermanySupervisor: Hermann J. Gröne

Sept - Oct 2002: Fellowship in nephropathologyMassachusetts General Hospital, Boston, MA, USASupervisor: Robert B. Colvin

Oct – Nov 2002: Fellowship in nephropathology Nephropathology Service, University of North Carolina, Chapel Hill, NC, USASupervisor: J. Charles Jennette

Licenses1997-Present: Medical License, Germany2004-Present: Board Certification for Pathology, Hannover, Germany2009-Present: License for Anatomical Pathology, College of Physicians and Surgeons of Alberta, Canada (General Register, license #020583)

2

M Mengel: CV

APPOINTMENTS & LEADERSHIP HIGHLIGHTS

Academic Appointments

Apr 2004 - Nov 2006: Attending Physician for Pathology (German equivalent to a faculty position)Institute of Pathology, Hannover Medical School, Hannover, Germany

Feb 2006 - Nov 2006: “Oberarzt” (German equivalent to Assistant Professor)Institute of Pathology, Hannover Medical School, Hannover, Germany

Dec 2006 - Oct 2008: Research AssociateAlberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Canada

Nov 2008 – Dec 2011: Lead Investigator, Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Canada

Nov 2008 – June 2014: Associate Professor (tenured in 2011), Department of Laboratory Medicine and Pathology, Division of Anatomical Pathology, University of Alberta, Edmonton, Canada

March 2011 – March 2014: Interim Chair, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada

April 2014 – present:Chair, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada

July 2014 - present: Professor (tenured), Department of Laboratory Medicine and Pathology, Division of Anatomical Pathology, University of Alberta, Edmonton, Canada

Clinical Appointments

1998-2006: Deputy Head, Laboratory for ImmunohistochemistryInstitute of Pathology, Hannover Medical School, Hannover, Germany

2000-2006: Head, Transplantation and Renal Pathology ServiceInstitute of Pathology, Hannover Medical School, Hannover, Germany

2000-2006: Head, Electron Microscopy LaboratoryInstitute of Pathology, Hannover Medical School, Hannover, Germany

2004-2005: Chief Coordinator, Undergraduate Medical EducationInstitute of Pathology, Hannover Medical School, Hannover, Germany

2004-2006: Attending Physician, Autopsy ServiceInstitute of Pathology, Hannover Medical School, Hannover, Germany

2004-2006: Attending Physician, Surgical Pathology

3

M Mengel: CV

Institute of Pathology, Hannover Medical School, Hannover, Germany

2008-2012: Head, Immunohistochemistry LaboratoryDivision of Anatomical Pathology, University of Alberta, Edmonton, Canada

2012-2013: Member Edmonton Zone Immunohistochemistry Steering Committee

2012-present: Chair, Provincial and Edmonton Zone Special Interest Group for Renal and Transplantation Pathology, Alberta Health Services

2012-present: Deputy Zone Clinical Department Head, Academic for the Edmonton Zone Laboratory Medicine and Pathology Services

2013 – present: Member Provincial Special Interest Group, Immunohistochemistry

2014: Evaluation team lead for “Academic/Research/Education”, AHS Request for Proposals (RFP) Laboratory Services Edmonton Zone

National & International Appointments & Activities

Committee Participation

2007-2009: Member, Renal Pathology Society Program Committee

2008-2013: Member, Banff Conference for Allograft Pathology Program Committee

2009-2010: Chair, Renal Pathology Society Program Committee

2010-2011: Chair, Renal Pathology Society Transplantation Committee

2010-2011: Member, Canadian Association of Pathologists National Standards Committee for Immunohistochemistry

2010-2013: Member, Canadian Society of Transplantation Scientific Program Committee

2010-2012: Chair, American Society of Transplantation Community of Practice for Transplant Diagnostics

2010-Present: Lead, Banff Initiative for Quality Assurance in Transplantation (BIFQUIT)

June 2013 – present:Member Executive Council, Alberta Transplant Institute, University of Alberta, Edmonton, Canada

2013: Chair International Advisory Committee – Pathology, World Transplant Congress 2014

2013-2014: Member, Research Committee, International Renal Pathology Society

2013-2016: Member, AST Grants Committee

4

M Mengel: CV

2013-Present: Member and Treasurer, Board of Trustees Banff Foundation for Allograft Pathology

2013-2017: Member, Board Canadian Society of Transplantation

2014-2015: Chair, Research Committee, International Renal Pathology Society

2015-2017: Treasurer, Canadian Society of Transplantation

Editorial Boards

2001-2009: Editorial Board MemberClinical Nephrology: Impact Factor 1.32

2010-2011: Editorial Board MemberCanadian Association of Pathologists Continuing Professional Development Case Study Program (CAP-CPD)

2013: Section Editor - PathologyCurrent Opinion in Organ Transplantation

2009-Present: Associate EditorAmerican Journal of Transplantation: Impact Factor 6.4.

Ad Hoc Reviewer

Scientific JournalsAmerican Journal of PathologyAmerican Journal of TransplantationJournal American Society of NephrologyKidney InternationalNephrology Dialysis and TransplantationPLoSONETransplantationHuman ImmunologyVirchows ArchiveThe Lancet

Granting Agencies2010: Women & Children’s health research institute (WCHRI), University of Alberta2010: Kidney Research UK2010: Czech Science Foundation2011: Transplant Research Foundation of British Columbia2012: Roche Organ Transplant Research Foundation2012: Medical Research Council, South Africa2013: Expert Committee, Canada Foundation for Innovation’s (CFI) Leaders Opportunity Fund (LOF)2014: Welcome Trust, UK; International Fellowship Competition2014: American Society of Transplantation

5

M Mengel: CV

2014: Alberta Health Services, Partnership for Research and Innovation in the Health System (PRIHS)2015: American Society of Transplantation2015: Alberta Health Services, Partnership for Research and Innovation in the Health System (PRIHS)

University / Faculty Promotion Committees2009: external reviewer for Dr. Helen Cathro, University of Virginia, promotion to Associate Professor2009: external reviewer for Dr. Rex Neal Smith, Harvard Medical School, Massachusetts General Hospital, promotion to Associate Professor2010: external reviewer for Dr. Jose Torrealba, University of Wisconsin, promotion to Associate Professor2011-present: member, Faculty Evaluation Committee, Faculty of Medicine and Dentistry, University of Alberta2013: external reviewer for Dr. Lynn Cornell, Medical College at Mayo Clinic, promotion to Associate Professor2013: internal reviewer for Dr. Stacey Hume, Department of Medical Genetics, University of Alberta, promotion to Associate Professor2014: external reviewer for Dr. Caigan Du, University of British Columbia, promotion to Associate Professor2015: Search and Selection Committee member, Chair Department of Earth and Atmospheric Science, University of Alberta2014: external reviewer for Dr. Serena Bagnasco, Johns Hopkins School of Medicine, promotion to Professor2015: Search and Selection Committee member, Chair Department of Psychology, University of Alberta

Professional Organizations

1998-2010: German Society of Pathology2002-Present: Renal Pathology Society2003-Present: American Society of Nephrology2004-2010: International Academy of Pathology2008-Present: European Working Group for Nephropathology2008-Present: American Society of Transplantation2009-Present: Canadian Society of Transplantation2009-Present: College of Physicians and Surgeons of Alberta2009-Present: Alberta and Canadian Medical Association2010-Present: European Society of Organ Transplantation2010-Present: United States Canadian Academy of Pathology2010-Present: European Society of Pathology2014-Present: The Transplantation Society

6

M Mengel: CV

AWARDS

Date Title Awarded By Details1998 Junior Award European

Association for Hematopathology

Six awards are given per year to the top abstracts submitted to the respective categories by young investigators, i.e. non-faculty level.

2003 Travel Grant Award for the World Congress of Nephrology

German Society of Nephrology

Four awards are given per year to the top abstracts submitted to the respective categories by young investigators, i.e. non-faculty level.

2006 Carl Ludwig Young Investigator Award

German Society of Nephrology

Awarded once per year. Based on outstanding research significantly contributing to the field of nephrology.

2008 Young Investigator Award

American Society of Transplantation

Twelve awards are given per year to the top twelve abstracts submitted to the annual meeting of the American Society of Transplantation by young investigators, i.e. non-faculty level.

2009 Gloria Gallo Research Award

Renal Pathology Society

Awarded once per year. Based on outstanding research significantly contributing to the field of renal pathology.

2009 2009 Biotest Award for Best Clinical Abstract

European Society of Organ Transplantation

Three awards are given per year. The best clinical oral presentations are selected by the European Society of Organ Transplantation Congress Grant Committee.

2011 Research Excellence Award

Canadian Society of Transplantation

Awarded once per year to an associate professor who has demonstrated:

- Excellence in scientific research- Significant promise to make a

substantial contribution to the field of transplantation

2011 Clinical Science Investigator Award (Associate Professor Level)

American Society of Transplantation

Awarded once per year to an associate professor who:

- Has made substantial contribution to the field of transplantation medicine.

- Shows signs of a bright future ahead in transplantation

7

M Mengel: CV

PUBLICATIONS & INTELLECTUAL PROPERTY

Summary 173 Peer-Reviewed, PubMed-listed publications (26 first authorships; 21 senior authorships) 21 Non-Peer-Reviewed publications, Books, Book Chapters, invited articles 198 Abstracts 2 patents

Published Peer-Reviewed Manuscripts (trainees underlined)

1. von Wasielewski,R., M.Mengel, R.Fischer, M.L.Hansmann, K.Hubner, J.Franklin, H.Tesch, U.Paulus, M.Werner, V.Diehl, and A.Georgii. 1997. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am.J.Pathol. 151:1123-1130.

2. von Wasielewski,R., M.Mengel, S.Gignac, L.Wilkens, M.Werner, and A.Georgii. 1997. Tyramine amplification technique in routine immunohistochemistry. J.Histochem.Cytochem. 45:1455-1459.

3. von Wasielewski,R., M.Mengel, M. Nolte, M.Werner. 1998 Influence of Fixation, Antibody Clones, and Signal Amplification on Steroid Receptor Analysis, Breast J 4:33-40.

4. Mengel,M., M.Werner, and R.von Wasielewski. 1999. Concentration dependent and adverse effects in immunohistochemistry using the tyramine amplification technique. Histochem.J. 31:195-200.

5. Woywodt,A., A.Schwarz, M.Mengel, H.Haller, H.Zeidler, and L.Kohler. 2001. Nephrotoxicity of selective COX-2 inhibitors. J.Rheumatol. 28:2133-2135.

6. Wilkens,L., M.Bredt, P.Flemming, Y.Schwarze, T.Becker, M.Mengel, R.von Wasielewski, J.Klempnauer, and H.Kreipe. 2001. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J.Mol.Diagn. 3:68-73.

7. Wilkens,L., M.Bredt, A.Flemming, M.Mengel, J.Klempnauer, H.Kreipe, and P.Flemming. 2002. Detection of chromosomal aberrations in well-differentiated hepatocellular carcinoma by bright-field in situ hybridization. Mod.Pathol. 15:470-475.

8. Wilkens,L., M.Bredt, P.Flemming, M.Mengel, T.Becker, J.Klempnauer, and H.Kreipe. 2002. Comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) in the diagnosis of hepatocellular carcinoma. J.Hepatobiliary.Pancreat.Surg. 9:304-311.

9. von Wasielewski,R., M.Mengel, B.Wiese, T.Rudiger, H.K.Muller-Hermelink, and H.Kreipe. 2002. Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am.J.Clin.Pathol. 118:675-682.

10. Schwarz,A., M.Mengel, W.Gwinner, U.Eisenberger, M.Hiss, J.Radermacher, A.Fiebeler, F.Abou-Rebyeh, and H.Haller. 2002. Protocol biopsy program after renal transplantation: Structure and first results. Transplantation Proceedings 34:2238-2239.

11. Schrader,A.J., O.Lechner, M.Templin, K.E.Dittmar, S.Machtens, M.Mengel, M.Probst-Kepper, A.Franzke, T.Wollensak, P.Gatzlaff, J.Atzpodien, J.Buer, and J.Lauber. 2002. CXCR4/CXCL12 expression and signalling in kidney cancer. Br.J.Cancer 86:1250-1256.

12. Schnarr,S., A.Wahl, B.Jurgens-Saathoff, M.Mengel, H.H.Kreipe, and H.Zeidler. 2002. Nodular fasciitis, erythema migrans, and oligoarthritis: manifestations of Lyme borreliosis caused by Borrelia afzelii. Scand.J.Rheumatol. 31:184-186.

8

M Mengel: CV

13. Ruhparwar,A., J.Tebbenjohanns, M.Niehaus, M.Mengel, T.Irtel, T.Kofidis, A.M.Pichlmaier, and A.Haverich. 2002. Transplanted fetal cardiomyocytes as cardiac pacemaker. Eur.J.Cardiothorac.Surg. 21:853-857.

14. Rudiger,T., H.Hofler, H.H.Kreipe, H.Nizze, U.Pfeifer, H.Stein, F.E.Dallenbach, H.P.Fischer, M.Mengel, R.von Wasielewski, and H.K.Muller-Hermelink. 2002. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am.J.Surg.Pathol. 26:873-882.

15. Rosenau,J., M.J.Bahr, R.von Wasielewski, M.Mengel, H.H.Schmidt, B.Nashan, H.Lang, J.Klempnauer, M.P.Manns, and K.H.Boeker. 2002. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplant 73:386-394.

16. Mengel,M., R.von Wasielewski, B.Wiese, T.Rudiger, H.K.Muller-Hermelink, and H.Kreipe. 2002. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J.Pathol. 198:292-299.

17. Karck,M., R.Meliss, M.Hestermann, M.Mengel, K.Pethig, A.Levitzki, S.Banai, G.Golomb, I.Fishbein, M.Chorny, and A.Haverich. 2002. Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplant 74:1335-1341.

18. Hecker,J.M., R.Lorenz, R.Appiah, B.Vangerow, M.Loss, R.Kunz, J.Schmidtko, M.Mengel, J.Klempnauer, S.Piepenbrock, G.Dickneite, H.Neidhardt, H.Ruckoldt, and M.Winkler. 2002. C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplant 73:688-694.

19. Gunzer,F., I.Hennig-Pauka, K.H.Waldmann, R.Sandhoff, H.J.Grone, H.H.Kreipe, A.Matussek, and M.Mengel. 2002. Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli. Am.J.Clin.Pathol. 118:364-375.

20. Gongoll,S., G.Peters, M.Mengel, P.Piso, J.Klempnauer, H.Kreipe, and R.von Wasielewski. 2002. Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 123:1478-1484.

21. Woywodt,A., M.Schroeder, W.Gwinner, M.Mengel, M.Jaeger, A.Schwarz, H.Haller, and M.Haubitz. 2003. Elevated numbers of circulating endothelial cells in renal transplant recipients. Transplantation 76:1-4.

22. Woywodt,A., M.Schroeder, M.Mengel, A.Schwarz, W.Gwinner, H.Haller, and M.Haubitz. 2003. Circulating endothelial cells are a novel marker of cyclosporine-induced endothelial damage. Hypertension 41:720-723.

23. Wedemeyer,H., J.G.Kuipers, K.Streetz, M.Mengel, I.Schedel, N.Kezmic, P.Meier, H.Zeidler, M.P.Manns, and S.Wagner. 2003. A rare manifestation of Behcet's syndrome: immunological correlates and successful treatment of an esophageal ulcer. Dig.Dis.Sci. 48:1385-1391.

24. Rudiger,T., H.Hofler, H.H.Kreipe, H.Nizze, U.Pfeifer, H.Stein, E.Dallenbach, H.P.Fischer, M.Mengel, R.von Wasielewski, and K.Muller-Hermelink. 2003. [Interlaboratory trial 2000 " Immunohistochemistry" of the German Society for Pathology and the Professional Association of German Pathologists]. Pathologe 24:70-78.

25. Radermacher,J., M.Mengel, S.Ellis, S.Stuht, M.Hiss, A.Schwarz, U.Eisenberger, M.Burg, F.C.Luft, W.Gwinner, and H.Haller. 2003. The renal arterial resistance index and renal allograft survival. N Engl J Med 349:115-124.

26. Peters,G., S.Gongoll, C.Langner, M.Mengel, P.Piso, J.Klempnauer, J.Ruschoff, H.Kreipe, and R.von Wasielewski. 2003. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 443:139-145.

27. Pape,L., T.Henne, G.Offner, J.Strehlau, J.H.Ehrich, M.Mengel, and P.C.Grimm. 2003. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function. Transplant 76:955-958.

9

M Mengel: CV

28. Mengel,M., H.Kreipe, and R.von Wasielewski. 2003. Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl.Immunohistochem.Mol.Morphol. 11:261-268.

29. Mengel,M., M.Marwedel, J.Radermacher, G.Eden, A.Schwarz, H.Haller, and H.Kreipe. 2003. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrology Dialysis Transplantation 18:1190-1196.

30. Matussek,A., J.Lauber, A.Bergau, W.Hansen, M.Rohde, K.E.Dittmar, M.Gunzer, M.Mengel, P.Gatzlaff, M.Hartmann, J.Buer, and F.Gunzer. 2003. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 102:1323-1332.

31. Gunzer,F., I.Hennig-Pauka, K.H.Waldmann, and M.Mengel. 2003. Gnotobiotic piglets as an animal model for oral infection with O157 and non-O157 serotypes of STEC. Methods Mol.Med. 73:307-327.

32. Furness,P.N., C.M.Philpott, M.T.Chorbadjian, M.L.Nicholson, J.L.Bosmans, B.L.Corthouts, J.J.P.M.Bogers, A.Schwarz, W.Gwinner, H.Haller, M.Mengel, D.Seron, F.Moreso, and C.Canas. 2003. Protocol biopsy of the stable renal transplant: A multicenter study of methods and complication rates. Transplant 76:969-973.

33. Fiebeler,A., M.Mengel, S.Merkel, H.Haller, and A.Schwarz. 2003. Diffuse C4d deposition and morphology of acute humoral rejection in a stable renal allograft. Transplant 76:1132-1133.

34. Pape,L., M.Mengel, G.Offner, M.Melter, J.H.Ehrich, and J.Strehlau. 2004. Renal arterial resistance index and computerized quantification of fibrosis as a combined predictive tool in chronic allograft nephropathy. Pediatr.Transplant 8:565-570.

35. Pape,L., M.Mengel, G.Offner, and J.H.Ehrich. 2004. Cyclosporin A-induced remission of primary membranous glomerulonephritis in a child. Nephrol.Dial.Transplant 19:3207.

36. Mengel,M., D.Jonigk, M.Marwedel, W.Kleeberger, M.Bredt, O.Bock, U.Lehmann, W.Gwinner, H.Haller, and H.Kreipe. 2004. Tubular chimerism occurs regularly in renal allografts and is not correlated to outcome. JASN 15:978-986.

37. Mengel,M., D.Jonigk, L.Wilkens, J.Radermacher, R.von Wasielewski, U.Lehmann, H.Haller, M.Mihatsch, and H.Kreipe. 2004. Chimerism of metanephric adenoma but not of carcinoma in kidney transplants. Am J Pathol 165:2079-2085.

38. Mengel,M., I.Mueller, M.Behrend, R.von Wasielewski, J.Radermacher, A.Schwarz, H.Haller, and H.Kreipe. 2004. Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection. Transpl.Int. 17:293-300.

39. Fiebeler,A., J.K.Park, D.N.Muller, C.Lindschau, M.Mengel, S.Merkel, B.Banas, F.C.Luft, and H.Haller. 2004. Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am.J.Kidney Dis. 43:286-295.

40. Bock,O., J.Schlue, M.Mengel, G.Busche, E.Serinsoz, and H.Kreipe. 2004. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders. J.Pathol. 203:609-615.

41. Bock,O., M.Neusch, G.Busche, M.Mengel, and H.Kreipe. 2004. Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis. Eur.J.Haematol. 72:239-244.

42. Bahlmann,F.H., R.Song, S.M.Boehm, M.Mengel, R.von Wasielewski, C.Lindschau, T.Kirsch, K.de Groot, R.Laudeley, E.Niemczyk, F.Guler, J.Menne, H.Haller, and D.Fliser. 2004. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110:1006-1012.

43. Wittke,S., M.Haubitz, M.Walden, F.Rohde, A.Schwarz, M.Mengel, H.Mischak, H.Haller, and W.Gwinner. 2005. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am.J.Transplant 5:2479-2488.

10

M Mengel: CV

44. Verhulst,A., M.Asselman, S.De Naeyer, B.A.Vervaet, M.Mengel, W.Gwinner, P.C.D'Haese, C.F.Verkoelen, and M.E.De Broe. 2005. Preconditioning of the distal tubular epithelium of the human kidney precedes nephrocalcinosis. Kidney Int. 68:1643-1647.

45. Serinsoz,E ., O.Bock, W.Gwinner, A.Schwarz, H.Haller, H.Kreipe, and M.Mengel. 2005. Local complement C3 expression is upregulated in humoral and cellular rejection of renal allografts. Am J Transplant 5:1490-1494.

46. Serinsoz,E ., O.Bock, T.Kirsch, H.Haller, U.Lehmann, H.Kreipe, and M.Mengel. 2005. Compartment-specific quantitative gene expression analysis after laser microdissection from archival renal allograft biopsies. Clin Nephrol 63:193-201.

47. Schwarz,A., W.Gwinner, M.Hiss, J.Radermacher, M.Mengel, and H.Haller. 2005. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 5:1992-1996.

48. Schwarz,A., M.Mengel, H.Haller, and J.Niedermeyer. 2005. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant 5:2582-2585.

49. Schwarz,A., M.Mengel, W.Gwinner, J.Radermacher, M.Hiss, H.Kreipe, and H.Haller. 2005. Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 67:341-348.

50. Mengel,M., U.Lehmann, and H.Kreipe. 2005. Chimerism after solid organ transplantation. Am J Transplant 5:3021.

51. Mengel,M., J.Bogers, J.L.Bosmans, D.Seron, F.Moreso, M.Carrera, W.Gwinner, A.Schwarz, M.De Broe, H.Kreipe, and H.Haller. 2005. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 5:1050-1056.

52. Mengel,M., K.Hebel, H.Kreipe, and R.von Wasielewski. 2005. Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer. Breast J. 11:34-40.

53. Koch,M., S.A.Joosten, M.Mengel, C.Van Kooten, L.C.Paul, and B.Nashan. 2005. Adoptive transfer of primed CD4+ T-lymphocytes induces pattern of chronic allograft nephropathy in a nude rat model. Transplant 79:753-761.

54. Horstmann,M., A.S.Merseburger, H.E.von der, J.Serth, G.Wegener, M.Mengel, G.Feil, J.Hennenlotter, U.Nagele, A.Anastasiadis, C.Bokemeyer, A.Stenzl, and M.Kuczyk. 2005. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J.Cancer Res.Clin.Oncol. 131:715-722.

55. Henke-Gendo,C., M.Mengel, M.M.Hoeper, K.Alkharsah, and T.F.Schulz. 2005. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am.J.Respir.Crit Care Med. 172:1581-1585.

56. Gwinner,W., S.Suppa, M.Mengel, L.Hoy, H.H.Kreipe, H.Haller, and A.Schwarz. 2005. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 5:1934-1941.

57. Doege,C., M.Koch, A.Heratizadeh, P.Sotonyi, M.Mengel, and B.Nashan. 2005. Chronic allograft nephropathy in athymic nude rats after adoptive transfer of primed T lymphocytes. Transpl.Int. 18:981-991.

58. Akdere,F ., O.Bock, U.Lehmann, E.Serinsoz, A.Haverich, H.Kreipe, and M.Mengel. 2005. Quantitative mRNA expression analysis of co-stimulatory molecules in sequential biopsies from heart allografts. Transpl.Int. 18:1197-1202.

59. Ziegler,E., F.Gueler, S.Rong, M.Mengel, O.Witzke, A.Kribben, H.Haller, U.Kunzendorf, and S.Krautwald. 2006. CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking. J.Am.Soc.Nephrol. 17:2521-2532.

60. Traub,F., M.Mengel, H.J.Luck, H.H.Kreipe, and R.von Wasielewski. 2006. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res.Treat. 99:185-191.

11

M Mengel: CV

61. Poling,J., M.Oezkur, K.Kogge, M.Mengel, H.Niemann, M.Winkler, A.Haverich, and K.Wiebe. 2006. Hyperacute rejection in ex vivo-perfused porcine lungs transgenic for human complement regulatory proteins. Transpl.Int. 19:225-232.

62. Peters,I., I.Tossidou, J.Achenbach, R.Woroniecki, M.Mengel, J.K.Park, M.Paschy, K.de Groot, H.Haller, and M.Schiffer. 2006. IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes. J.Am.Soc.Nephrol. 17:1644-1656.

63. Merkel,S., N.Mogilevskaja, M.Mengel, H.Haller, and A.Schwarz. 2006. Side effects of sirolimus. Transplantation Proceedings 38:714-715.

64. Lehnhardt,A., M.Mengel, L.Pape, J.H.H.Ehrich, G.Offner, and J.Strehlau. 2006. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. Am J Transplant 6:847-851.

65. Kumpers,P., A.Herrmann, J.Lotz, M.Mengel, and A.Schwarz. 2006. A blue kidney--chronic renal failure as a consequence of siderosis in paroxysmal nocturnal hemoglobinuria? Clin.Nephrol. 66:210-213.

66. Durisin,M., M.Mengel, A.Beilken, F.Donnerstag, T.Lenarz, and T.Stover. 2006. [Embryonal rhabdomyosarcoma of the orbita]. Laryngorhinootologie 85:124-127.

67. Doe,J.Y., M.Funk, M.Mengel, E.Doehring, and J.H.Ehrich. 2006. Nephrotic syndrome in African children: lack of evidence for 'tropical nephrotic syndrome'? Nephrol.Dial.Transplant 21:672-676.

68. Divchev,D., E.K.Podewski, M.Mengel, G.P.Meyer, H.Drexler, and A.Schaefer. 2006. Inflammatory, abscess-forming foreign body reaction mimics a thrombus formation on an atrial septal defect closure device: A commented case report. Eur.J.Echocardiogr.

69. Deppenmeier,S., O.Bock, M.Mengel, H.Niemann, W.Kues, E.Lemme, D.Wirth, K.Wonigeit, and H.Kreipe. 2006. Health status of transgenic pigs expressing the human complement regulatory protein CD59. Xenotransplantation 13:345-356.

70. Brocker,V ., U.Lehmann, F.Langer, T.G.Fellous, M.Mengel, M.Brittan, M.Bredt, S.Milde, T.Welte, M.Eder, A.Haverich, M.R.Alison, and H.Kreipe. 2006. [Fibroblasts of recipient origin contribute to broncholitis obliterans in human lung transplants]. Verh.Dtsch.Ges.Pathol. 90:277-285.

71. Brocker,V ., F.Langer, T.G.Fellous, M.Mengel, M.Brittan, M.Bredt, S.Milde, T.Welte, M.Eder, A.Haverich, M.R.Alison, H.Kreipe, and U.Lehmann. 2006. Fibroblasts of recipient origin contribute to bronchiolitis obliterans in human lung transplants. Am.J.Respir.Crit Care Med. 173:1276-1282.

72. Athanassiadi,K., C.Grothusen, M.Mengel, and A.Haverich. 2006. Primary leiomyosarcoma of the pulmonary artery: Is aggressive treatment justified for a long survival? J.Thorac.Cardiovasc.Surg. 132:435-436.

73. Ye,F.C., D.J.Blackbourn, M.Mengel, J.P.Xie, L.W.Qian, W.Greene, I.T.Yeh, D.Graham, and S.J.Gao. 2007. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J.Virol.

74. Stuht,S ., W.Gwinner, I.Franz, A.Schwarz, D.Jonigk, H.Kreipe, D.Kerjaschki, H.Haller, and M.Mengel. 2007. Lymphatic neoangiogenesis in human renal allografts: results from sequential protocol biopsies. Am.J.Transplant 7:377-384.

75. Solez,K., R.B.Colvin, L.C.Racusen, B.Sis, P.F.Halloran, P.E.Birk, P.M.Campbell, M.Cascalho, A.B.Collins, A.J.Demetris, C.B.Drachenberg, I.W.Gibson, P.C.Grimm, M.Haas, E.Lerut, H.Liapis, R.B.Mannon, P.B.Marcus, M.Mengel, M.J.Mihatsch, B.J.Nankivell, V.Nickeleit, J.C.Papadimitriou, J.L.Platt, P.Randhawa, I.Roberts, L.Salinas-Madriga, D.R.Salomon, D.Seron, M.Sheaff, and J.J.Weening. 2007. Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy ('CAN'). Am.J.Transplant 7:518-526.

76. Mengel,M., W.Gwinner, A.Schwarz, R.Bajeski, I.Franz, V.Brocker, T.Becker, M.Neipp, J.Klempnauer, H.Haller, and H.Kreipe. 2007. Infiltrates in protocol biopsies from renal allografts. Am.J.Transplant 7:356-365.

12

M Mengel: CV

77. Mengel,M., J.R.Chapman, F.G.Cosio, M.W.Cavaille-Coll, H.Haller, P.F.Halloran, A.D.Kirk, M.J.Mihatsch, B.J.Nankivell, L.C.Racusen, I.S.Roberts, D.N.Rush, A.Schwarz, D.Seron, M.D.Stegall, and R.B.Colvin. 2007. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am.J.Transplant 7:512-517.

78. Koch,M., M.Mengel, D.Poehnert, and B.Nashan. 2007. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplant 83:498-505.

79. Woywodt,A., S.Hellweg, A.Schwarz, R.M.Schaefer, and M.Mengel. 2007. A wild zebra chase. Nephrol.Dial.Transplant.

80. Menne,J., J.K.Park, N.Shushakova, M.Mengel, M.Meier, and D.Fliser. 2007. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc.Nephrol. 18:2046-2053.

81. Meier,M., J.Menne, J.K.Park, M.Holtz, F.Gueler, T.Kirsch, M.Schiffer, M.Mengel, C.Lindschau, M.Leitges, and H.Haller. 2007. Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J.Am.Soc.Nephrol. 18:1190-1198.

82. Meier,M., A.Beigel, L.Schiffer, J.Lotz, M.Hiss, M.Mengel, H.Haller, and A.Schwarz. 2007. Magnetic resonance imaging in a patient with chronic lithium nephropathy. Nephrol.Dial.Transplant 22:278-279.

83. Gwinner,W., U.Erdbruegger, M.Mengel, C.Hafer, J.Kittner, T.Witte, B.Voelker, and H.Haller. 2007. Scleroderma-like acute renal crisis in a patient with scleromyxedema. Nephrol.Dial.Transplant 22:2063-2067.

84. Drube,J., C.Geerlings, R.Taylor, M.Mengel, and J.H.Ehrich. 2007. Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine A. Pediatr.Nephrol. 22:600-602.

85. Kumpers,P., F.Gueler, S.Rong, M.Mengel, I.Tossidou, I.Peters, H.Haller, and M.Schiffer. 2007. Leptin is a coactivator of TGF-beta in unilateral ureteral obstructive kidney disease. Am J Physiol Renal Physiol 293:F1355-F1362.

86. Hentschel,D.M., M.Mengel, L.Boehme, F.Liebsch, C.Albertin, J.V.Bonventre, H.Haller, and M.Schiffer. 2007. Rapid screening of glomerular slit diaphragm integrity in larval zebrafish. Am J Physiol Renal Physiol.

87. Merseburger,A.S., J.Serth, H.E.von der, A.Kobierski, U.Wegener, M.Mengel, U.Jonas, and M.Kuczyk. 2007. Heterogeneous p27(Kip1) expression within primary renal cell cancers, their invasive margins and peritumoral renal parenchyma correlation with pathological and prognostic features. Urol.Int. 79:164-169.

88. Mueller,T.F., G.Einecke, J.Reeve, B.Sis, M.Mengel, Jhangri.G., S.Bunnag, J.Cruz, D.Wishart, C.Meng, G.Broderick, B.Kaplan, and P.F.Halloran. 2007. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 12: 2712-2722.

89. Mengel,M., B.Sis, and P.F.Halloran. 2007. SWOT analysis of Banff: Strengths, Weaknesses, Opportunities, and Threats of the international Banff consensus process and classification system for renal allograft pathology. Am J Transplant 7:2221-2226.

90. Famulski,K.S., G.Broderick, K.Hay, J.Cruz, B.Sis, M.Mengel, and P.F.Halloran. 2007. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 7:2483-2495.

91. Mueller,T.F., J.Reeve, G.S.Jhangri, M.Mengel, Z.Jacaj, L.Cairo, M.Obeidat, G.Todd, R.Moore, K.S.Famulski, D.Wishart, B.Sis, K.Solez, B.Kaplan, and P.F.Halloran. 2008 The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function. Am J Transplant 8: 78-85.

92. D. Jonigk , U. Lehman, S. Stuht, M. Wilhelmi, A. Haverich, H. Kreipe, and M. Mengel. 2007 Recipient derived neoangiogenesis of arterioles and lymphatics in Quilty-lesions of cardiac allografts. Transplant 84:1335-1342.

13

M Mengel: CV

93. de Groot K, Kuklik K, Brocker V, Schwarz A, Gwinner W, Kreipe H, Haller H, Fliser D, Mengel M. 2008 Toll-Like Receptor 2 and Renal Allograft Function. Am J Nephrol. 8;28(4):583-588

94. Hidalgo,L.G., G.Einecke, K.Allanach, M.Mengel, B.Sis, T.F.Mueller, and P.F.Halloran. 2008 The transcriptome of human cytotoxic T cells. 2. Measuring the burden of CTL associated transcripts in human kidney transplants. Am J Transplant 8:637-646.

95. Ramackers W, Friedrich L, Tiede A, Bergmann S, Schuettler W, Schuerholz T, Mengel M, Goudeva L, Ganser A, Klempnauer J, Piepenbrock S, Winkler M. 2008 Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. Xenotransplantation. 15(1):46-55

96. Gibson, W. Gwinner ,V. Brőcker, B. Sis, J. Riopel, I. S.D. Roberts, I. Scheffner, G. S. Jhangri, M. Mengel. 2008 Peritubular capillaritis in renal allografts: Prevalence, scoring system, reproducibility, and clinicopathological correlates. Am J Transplant 8:819-825.

97. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M. 2008 Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions. Am J Transplant 8:753-760.

98. K. Allanach, M. Mengel, G. Einecke, B. Sis, L.G. Hidalgo, Th. Mueller, P.F. Halloran. 2008 Comparing microarray versus RT-PCR assessment of renal allograft biopsies: similar performance despite different dynamic ranges. Am J Transplant 8: 1006-1015.

99. Ashton-Chess J, Giral M, Mengel M, Renaudin K, Foucher Y, Gwinner W, Braud C, Dugast E, Quillard T, Thebault P, Chiffoleau E, Braudeau C, Charreau B, Soulillou JP, Brouard S. 2008 Tribbles Homolog 1: a novel biomarker of chronic antibody-mediated rejection. J.Am.Soc.Nephrol 19: 1116-1127.

100. Gueler F, Rong S, Mengel M, Park JK, Kiyan J, Kirsch T, Dumler I, Haller H, Shushakova N. 2008 Renal Urokinase-Type Plasminogen Activator (uPA) Receptor but not uPA Deficiency Strongly Attenuates Ischemia Reperfusion Injury and Acute Kidney Allograft Rejection. J Immunol. 15:1179-89.

101. M. Mengel, O. Bock, M. Priess, H. Haller, H. Kreipe, W. Gwinner. 2008 Expression of pro- and anti-fibrotic genes in protocol biopsies from renal allografts with interstitial fibrosis and tubular atrophy. Clin Nephrol 69: 408-416.

102. G. Einecke, J. Reeve, M. Mengel, B. Sis, S. Bunnag, Th.F. Mueller, P.F. Halloran. 2008 Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am J Transplant 8: 1434-1443.

103. S. Bunnag, K. Allanach, G.S. Jhangri, B. Sis, G. Einecke, M. Mengel, Th. Mueller, P.F. Halloran. 2008 FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post-transplant but not with favorable outcomes. Am J Transplant 8: 1423-1433.

104. Koch M, Broecker V, Heratizadeh A, Doege C, Strehlau J, Mengel M, Nashan B. 2008 Induction of chronic renal allograft injury by injection of a monoclonal antibody against a donor MHC Ib molecule in a nude rat model. Transpl Immunol 181: 187-191.

105. W. Gwinner, K. Hinzmann, U. Erdbruegger, I. Scheffner, V. Broecker, B. Vaske, H. Kreipe, H. Haller, A. Schwarz, M. Mengel. 2008 Acute Tubular Injury in Protocol Biopsies of Renal Grafts: Prevalence, Associated Factors and Effect on Long-term Function. Am J Transplant 8:1684-93.

106. Achenbach J, Mengel M, Tossidou I, Peters I, Park JK, Haubitz M, Ehrich JH, Haller H, Schiffer M. 2008 Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases. Nephrol Dial Transplant 10: 3138-3145.

107. Kayser D, Einecke G, Famulski KS, Mengel M, Sis B, Zhu LF, Halloran PF. 2008 Donor Fas is not necessary for T-cell-mediated rejection of mouse kidney allografts. Am J Transplant. 8:2049-2055.

108. Gueler F, Rong S, Gwinner W, Mengel M, Bröcker V, Schön S, Greten TF, Hawlisch H, Polakowski T, Schnatbaum K, Menne J, Haller H, Shushakova N. 2008 Complement 5a Receptor Inhibition Improves Renal Allograft Survival. J Am Soc Nephrol 19(12): 2302-2312.

14

M Mengel: CV

109. M. Mengel, B. Sis 2008 An appeal for zero-time biopsies in renal transplantation. Am J Transplant 8(11): 2181-2182.

110. M. Mengel, J. Reeve, S. Bunnag, G. Einecke, B. Sis, Th. Mueller, B. Kaplan, Ph.F. Halloran 2009 Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant 9(1): 169-178.

111. Ghodsizad A, Niehaus M, Koegler G, Martin U, Wernet P, Bara C, Khaladj N, Loos A, Makoui M, Thiele J, Mengel M, Karck M, Klein HM, Haverich A, Ruhparwar A. 2009 Transplanted human cord blood derived unrestricted somatic stem cells improve left-ventricular function and prevent left-ventricular dilation and scar formation after acute myocardial infarction. Heart 25(1): 27-35.

112. Einecke G, Mengel M, Hidalgo L, Allanach K, Famulski KS, Halloran PF. 2009 The early course of kidney allograft rejection: defining the time when rejection begins. Am J Transplant 9(3): 483-493.

113. Bunnag S, Einecke G, Reeve J, Jhangri GS, Mueller TF, Sis B, Hidalgo LG, Mengel M, Kayser D, Kaplan B, Halloran PF. 2009 Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol. 20(5):1149-60.

114. Reeve J, Einecke G, Mengel M, Sis B, Kayser N, Kaplan B, Halloran PF. 2009 Diagnosing Rejection in Renal Transplants: A Comparison of Molecular- and Histopathology-Based Approaches. Am J Transplant 9(8): 1802-1810

115. Mengel M, Reeve J, Bunnag S, Einecke G, Jhangri GS, Sis B, Famulski K, Guembes-Hidalgo L, Halloran PF. 2009 Scoring Total Inflammation Is Superior to the Current Banff Inflammation Score in Predicting Outcome and the Degree of Molecular Disturbance in Renal Allografts. Am J Transplant 9(8): 1859-1867

116. Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, Józsi M. 2009 Autoimmune forms of thrombotic micorangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Mol Immunol. Sep;46 (14):2801-7.

117. Hidalgo LG, Campbell PM, Sis B., Einecke G, Mengel M, Chang J, Halloran PF. 2009 De novo donor specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant; Nov;9(11):2532-41

118. Einecke G, Sis B., Reeve J, Mengel M, Campbell PM, Hidalgo LG, Halloran PF. 2009 Antibody mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant; Nov;9(11):2520-31

119. Poehnert D, Broecker V, Mengel M, Nashand B, Koch M. 2010 Induction of chronic renal allograft dysfunction in a rat model with complete and exclusive MHC incompatibility. Transpl Immunol. Feb;22(3-4):137-143

120. Sis B, Mengel M, M Haas, R Colvin, P Halloran, L Racusen, K Solez, W Baldwin, E Bracamonte, V Broecker, F Cosio, A Demetris, C Drachenberg, G Einecke, J Gloor, D Glotz, E Kraus, C Legendre, H Liapis, R Mannon, B Nankivell, V Nickeleit, J Papadimitriou, P Randhawa, H Regele, K Renaudin, E Rodriguez, D Seron, S Seshan, M Suthanthiran, B Wasowska, A Zachary, A Zeevi. 2010 Banff ’09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups. Am J Transplant. Mar;10(3):464-71

121. Sis B, Einecke G, Chang J, Hidalgo LG, Mengel M, Kaplan B Halloran PF. 2010 Cluster analysis of lesions in kidney transplant biopsies: Microcirculation changes, tubulointerstitial inflammation, and scarring. Am J Transplant. Feb;10(2):421-30

122. Famulski KS, Einecke G, Sis B, Mengel M, Hidalgo LG, Kaplan B, Halloran PF. 2010 Defining the Canonical Form of T-Cell-Mediated Rejection in Human Kidney Transplants. Am J Transplant. Apr;10(4):810-20

123. Ashton-Chess J, Le Mai H, Jovanovic V, Renaudin K, Foucher Y, Giral M, Moreau A, Dugast E, Mengel M, Racapé M, Danger R, Usal C, Smit H, Guillet M, Gwinner W, Le Berre L, Dantal J, Soulillou JP, Brouard S. 2010 Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney Int. May;77(10):880-90

15

M Mengel: CV

124. Einecke G, Reeve J, Sis B, Mengel M, Hidalgo L, Famulski K, Matas A, Kasiske B, Kaplan B, Halloran. 2010 A molecular classifier for predicting future graft loss in late human kidney transplant biopsies. J Clin Invest. Jun 1;120(6):1862-72

125. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, Chang J, Halloran PF. 2010 NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. Aug;10(8):1812-22.

126. Mengel M, Sis B, Kim D, Chang J, Famulski KS, Hidalgo LG, Einecke G, de Freitas D, Tymchak W, Burton J,Halloran PF. 2010 The molecular phenotype of heart transplant biopsies: Relationship to Histopathological and Clinical Variables. Am J Transplant. Sept;10(9):2105-15.

127. P. F. Halloran, D. G. De Freitas, G. Einecke, K. S. Famulski, L. G. Hidalgo, M. Mengel, J. Reeve, J. Sellares and B. Sis. 2010 Personal Viewpoint: An Integrated View of Molecular Changes, Histopathology and Outcomes in Kidney Transplants. Am J Transplant. Oct;10(10):2223-20

128. P. F. Halloran, D. G. De Freitas, G. Einecke, K. S. Famulski, L. G. Hidalgo, M. Mengel, J. Reeve, J. Sellares and B. Sis. 2010 Personal Viewpoint: The Molecular Phenotype of Kidney Transplants. Am J Transplant. Oct;10(10):2215-22

129. G. Einecke, D. Kayser, J. M. Vanslambrouck, B. Sis, J. Reeve, M. Mengel, K. S. Famulski, C. G. Bailey, J. E. J. Rasko and P. F. Halloran. 2010 Loss of Solute Carriers in T Cell-Mediated Rejection in Mouse and Human Kidneys: An Active Epithelial Injury–Repair Response Am J Transplant. Oct;10(10):2241–2251

130. D Jonigk , M Merk, K Hussein, L Maegel, K Theophile, M Muth, U Lehmann, C Bockmeyer, M Mengel, J Gottlieb, A Haverich, H Golpon, H Kreipe, F Laenger. 2011 Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol. Feb;178(2):599-608

131. Sellarés J, de Freitas DG, Mengel M, Sis B, Hidalgo LG, Matas AJ, Kaplan B, Halloran PF. 2011 Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant. Mar;11(3):489-99

132. M Mengel, J Chang, D Kayser, W Gwinner, A Schwarz, G Einecke, V Broecker, K Famulski, DG de Freitas, L Guembes-Hidalgo, B Sis, H Haller, PF Halloran. 2011 The molecular phenotype of six-week protocol biopsies from human renal allografts: Reflections of prior injury but not future course. Am J Transplant. Apr;11(4):708-18

133. Metzger J, Chatzikyrkou C, Broecker V, Schiffer E, Jaensch L, Iphoefer A, Mengel M, Mullen W, Mischak H, Haller H, Gwinner W. 2011 Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin Appl. Jun;5(5-6):322-33.

134. Mengel M, Mihatsch M, Halloran P. 2011 Histological Characteristics of Calcineurin Inhibitor Toxicity-There Is No Such Thing as Specificity! Am J Transplant. Dec;11(12):2549-50

135. Erdbruegger U, Scheffner I, Mengel M, Schwarz A, Verhagen W, Haller H, Gwinner W. 2012 Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant. Jan; 27(1):435-43.

136. de Freitas D, Sellarés J, Mengel M, Chang J, Hidalgo L, Famulski K, Sis B, Einecke G, Halloran PF. 2012 The nature of biopsies with “Borderline Rejection” and prospects for eliminating this category. Am J Transplant. Jan; 12(1):191-201.

137. Sellarés J, de Freitas D, Mengel M, Reeve J, Einecke G , Sis B, Hidalgo L, Famulski K, Matas A, Halloran PF 2012 Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and non-adherence. Am J Transplant. Feb; 12(2):388-99.

138. M Mengel, B Sis, M Haas, R.B. Colvin, P.F. Halloran, L.C. Racusen, K Solez, L Cendales, A.J. Demetris, C.B. Drachenberg, C. Farver, E.R Rodriguez, W.D Wallace, D Glotz. 2012 Banff 2012 Meeting Report: New Concepts in Antibody-Mediated Rejection. Am J Transplant. Mar;12(3):563-70.

139. Bröcker V , Schubert V, Scheffner I, Schwarz A, Hiss M, Becker JU, Scherer R, Haller H, Kreipe HH,

16

M Mengel: CV

Mengel M, Gwinner W. 2012 Arteriolar Lesions in Renal Transplant Biopsies: Prevalence, Progression, and Clinical Significance. Am J Pathol. May;180(5):1852-62.

140. Ozluk Y, Blanco PL, Mengel M, Solez K, Halloran PF, Sis B. 2012 Superiority of virtual microscopy versus light microscopy in transplantation pathology. Clin Transplant. Mar;26(2):336-44.

141. Sis B, Jhangri G, Riopel J, Chang J, de Freitas D, Hidalgo L, Mengel M, Matas A, Halloran PF. 2012 A new scoring system and algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant. May;12(5):1168-79.

142. Hidalgo LG, Sellares J, Sis B, Mengel M, Chang J, Halloran PF. 2012 Interpreting NK Cell Transcripts Versus T-Cell Transcripts in Renal Transplant Biopsies. Am J Transplant. May;12(5):1180-91

143. Famulski KS, de Freitas DG, Kreepala C, Chang J, Sellares J, Sis B, Einecke G, Mengel M, Reeve J, Halloran PF. 2012 Molecular Phenotypes of Acute Kidney Injury in Kidney Transplants. J Am Soc Nephrol. 2012 May;23(5):948-58

144. Mengel M, Husain S, Hidalgo L, Sis B. 2012 Phenotypes of antibody-mediated rejection in organ transplants. Transpl Int. Jun;25(6):611-22.

145. Mueller-Deile J, Kümpers P, Achenbach J, Park JK, Mengel M, Haller H, Schiffer M. 2012 Podocalyxin-positive glomerular epithelial cells in urine correlate with a positive outcome in FSGS. J Nephrol, Sep;25(5):802-809.

146. Ahmad Saliba K ., Colak A., Gourishankar S. Mengel M. 2012 Images in Transplantation: Acute Renal Failure in a Kidney Donor. Am J Transplant. Volume 12, Issue 11, 2012, 3158–3160

147. Schiffer L, Schiffer M, Merkel S, Schwarz A, Mengel M, Jürgens C, Schroeder C, Zoerner AA, Püllmann K, Bröcker V, Becker JU, Dämmrich ME, Träder J, Großhennig A, Biertz F, Haller H, Koch A, Gwinner W. 2012 Rationale and design of the RIACT--study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial. Trials. Oct 26;13(1):199.

148. Mengel M, Campbell P, Gebel H, Randhawa P, Rodriguez ER, Colvin R, Conway J, Hachem R, Halloran P, Keshavjee S, Nickerson P, Murphey C, O'Leary J, Reeve J, Tinckam K, Reed EF. 2013 Precision Diagnostics in Transplantation: From Bench to Bedside. Am J Transplant Mar;13(3):562-8.

149. Reeve J, Sellarés J, Mengel M, Sis B, Skene A, Hidalgo L, de Freitas D, Famulski KS, Halloran PF. 2013 Molecular Diagnosis of T Cell-Mediated Rejection in Human Kidney Transplant Biopsies. Am J Transplant Mar;13(3):645-55.

150. Sellarés J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, de Freitas D, Kreepala C, Hidalgo LG, Famulski KS, Halloran PF. 2013 Molecular Diagnosis of Antibody-Mediated Rejection in Human Kidney Transplants. Am J Transplant Apr;13(4):971-83.

151. Mengel M, Chan S, Climenhaga J, Kushner YB, Regele H, Colvin RB, Randhawa P. 2013 Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): Reproducibility of C4d Immunohistochemistry in Kidney Allografts. Am J Transplant May;13(5):1235-45

152. D'Agati VD, Mengel M. 2013 The Rise of Renal Pathology in Nephrology: Structure Illuminates Function. Am J Kidney Dis Jun;61(6):1016-25.

153. Jeyakanthan M, Zhou X, Tao K, Mengel M, Rajotte RV, Larsen I, West LJ. 2013 Failure of Neonatal B-Cell Tolerance Induction by ABO-Incompatible Kidney Grafts in Piglets. Transplantation Sep;96(6):519-528

154. Hueper K, Rong S, Gutberlet M, Hartung D, Mengel M, Lu X, Haller H, Wacker F, Meier M, Gueler F. 2013 T2 Relaxation Time and Apparent Diffusion Coefficient for Noninvasive Assessment of Renal Pathology After Acute Kidney Injury in Mice: Comparison With Histopathology. Invest Radiol. Dec;48(12):834-42.

155. Hueper K, Gutberlet M, Rong S, Hartung D, Mengel M, Lu X, Haller H, Wacker F, Meier M, Gueler F: 2014 Acute Kidney Injury: Arterial Spin Labeling to Monitor Renal Perfusion Impairment in Mice--Comparison with Histopathologic Results and Renal Function. Radiology. Jan;270(1):117-24

17

M Mengel: CV

156. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; as the Banff meeting report writing committee. 2014 Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. Feb;14(2):272-83.

157. Mengel M, Chong A, Rothstein DM, Zorn E, Maltzman JS. 2014 AST Cutting Edge of Transplantation 2013 Meeting Report: A Comprehensive Look at B Cells and Antibodies in Transplantation. Am J Transplant. 2014 Mar;14(3):524-30.

158. Farris AB, Chan S, Climenhaga J, Adam B, Bellamy CO, Serón D, Colvin RB, Reeve J, Mengel M. 2014 Banff fibrosis study: multicenter visual assessment and computerized analysis of interstitial fibrosis in kidney biopsies. Am J Transplant. Apr;14(4):897-907

159. Hueper K, Peperhove M, Rong S, Gerstenberg J, Mengel M, Meier M, Gutberlet M, Tewes S, Barrmeyer A, Chen R, Haller H, Wacker F, Hartung D, Gueler F. 2014 T1-mapping for assessment of ischemia-induced acute kidney injury and prediction of chronic kidney disease in mice. Eur Radiol., Sep;24(9):2252-60.

160. Bröcker V, Mengel M. 2014 Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation. Pediatr Nephrol Oct;29(10):1939-49.

161. Rong S, Hueper K, Kirsch T, Greite R, Klemann C, Mengel M, Meier M, Menne J, Leitges M, Susnik N, Meier M, Haller H, Shushakova N, Gueler F. 2014 Renal PKC epsilon deficiency attenuates acute kidney injury and ischemic allograft injury via TNF alpha dependent inhibition of apoptosis and inflammation. Am J Physiol Renal Physiol, Sep 15;307(6):F718-26.

162. Adam B , Randhawa P, Chan S, Zeng G, Regele H, Kushner YB, Colvin RB, Reeve J, Mengel M. 2014 Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): Reproducibility of Polyomavirus Immunohistochemistry in Kidney Allografts. Am J Transplant. 2014 Sep;14(9):2137-47.

163. Cheung CC, Banerjee D, Barnes PJ, Berendt RC, Butany J, Canil S, Clarke BA, El-Zimaity H, Garratt J, Geldenhuys L, Gilks CB, Manning L, Mengel M, Perez-Ordonez B, Pilavdzic D, Riddell R, Swanson PE, Torlakovic EE. 2014 Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: Guidelines for the Preparation, Release, and Storage of Unstained Archived Diagnostic Tissue Sections for Immunohistochemistry. Am J Clin Pathol. 2014 Nov;142(5):629-33.

164. Butler CR, Kim DH, Chow K, Toma M, Thompson R, Mengel M, Haykowsky M, Pearson GJ, Paterson I. Cardiovascular MRI Predicts 5-Year Adverse Clinical Outcome in Heart Transplant Recipients. Am J Transplant. 2014 Sep;14(9):2055-61.

165. Broecker V, Mengel M. The significance of histological diagnosis in renal allograft biopsies in 2014. Transpl Int. 2015 Feb;28(2):136-45.

166. Gueler F, Shushakova N, Mengel M, Hueper K, Chen R, Liu X, Park JK, Haller H, Wensvoort G, Rong S. A novel therapy to attenuate acute kidney injury and ischemic allograft damage after allogenic kidney transplantation in mice. PLoS One. 2015 Jan 24;10(1):

167. Loupy A, Viglietti D, Mengel M. Complement Inhibition in HLA-Incompatible Kidney Transplants: Persisting Antibody-Mediated Injury Despite Marked Decrease of Clinical ABMR. Am J Transplant. 2015 May;15(5):1139-40.

168. Butler CR, Savu A, Bakal JA, Toma M, Thompson R, Chow K, Wang H, Kim DH, Mengel M, Haykowsky M, Pearson GJ, Kaul P, Paterson I. Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection. J Heart Lung Transplant. 2015 May;34(5):643-50.

169. Adam B , Mengel M. Molecular Nephropathology: Ready for Prime Time? Am J Physiol Renal Physiol. 2015, in press

18

M Mengel: CV

170. Jeyakanthan M, Tao K, Zou L, Meloncelli PJ, Lowary TL, Suzuki K, Boland D, Larsen I, Burch M, Shaw N, Beddows K, Addonizio L, Zuckerman W, Afzali B, Kim DH, Mengel M, Shapiro AM, West LJ. Chemical Basis for Qualitative and Quantitative Differences Between ABO Blood Groups and Subgroups: Implications for Organ Transplantation. Am J Transplant. 2015, in press

171. Adam B, Mengel M. Transplant biopsy beyond light microscopy. BMC Nephrol. 2015, in press172. Hueper K, Hensen B, Gutberlet M, Chen R, Hartung D, Barrmeyer A, Meier M, Li W, Jang MS,

Mengel M, Wacker F, Rong S, Gueler F. Kidney Transplantation: Multiparametric Functional Magnetic Resonance Imaging for Assessment of Renal Allograft Pathophysiology in Mice. Invest Radiol. 2015 in press

173. Erdbruegger U, Scheffner I, Mengel M, Schwarz A, Haller H, Gwinner W. Long-term impact of CMV infection on the allograft and on patient survival in renal transplant patients with protocol biopsies. Am J Physiol Renal Physiol. 2015 in press

Non-Peer-Reviewed Publications (Books, Book Chapters, Book reviews, Invited Articles and commentaries)

1. R. von Wasielewski, Mengel M. Gewebe-Arrays: Ein neues Instrument zur Evaluation von Prognosefaktoren und zur Qualitätssicherung in der Tumorpathologie. Forschungsbericht 2002 der Medizinischen Hochschule Hannover, S. 543-547

2. Mengel M, Kreipe H, Haller H, Schwarz A. Recurrent lupus nephritis in a rejected renal allograft. Nephrology 7: 262-266 (2002)

3. Mengel M, Kreipe H., Radermacher J. Pathologie von Virusinfektionen nach Nierentransplantation. Nieren- und Hochdruckkrankheiten, Jg. 33, Nr. 7, S. 365-375 (2004)

4. Mengel M, Lehmann U., Jonigk D., Kleeberger J., Kreipe H. Role of stem cell trafficking and donor-recipient cellular chimerism in lung transplantation. Curr Opin Organ Transpl 9: 332-336 (2004)

5. Mengel M, Schwarz A. Ungewöhnliche Befunde in Protokollbiopsien nach Nierentransplantation. Spektrum der Nephrologie 19, Nr. 6, 2006, pp 11-17

6. Mengel M. Protocol Biopsies and the diagnosis of humoral rejection. Biopsia de Protocolo en el Transplante renal, edit by Manuel Arias Rodriguez and Daniel Seron. Roche Pharma Press, Madrid, Spain, 2007, pp 51-70

7. Mengel,M., V.Brocker, A.Schwarz, H.Haller, and W.Gwinner. 2007. No evidence for relationsship between infiltrates in renal protocol biopsies and outcome. Am J Transplant 7:2639-2640.

8. Licht C and Mengel M. Membranoproliferative Glomerulonephritis. Textbook of Comprehensive Pediatric Nephrology, 1st edition, Chapter 17. edit. By Denis F. Geary and Franz Schaefer, 2008, pp 269-290

9. Mengel M. Protokollbiopsie nach Nierentransplantation Wissenschaftliches Interesse oder notwendige Frühdiagnostik? Der Nephrologe, Vol 3, (3, May), 2008, pp 216-221

10. Mengel M. Transplantation Pathology edited by Phillip Ruiz. Am J Transplant. Vol 9 (9), 2009, p2203

11. Mengel M. The kidney transplant: new horizons. Curr Opin Nephrol Hypertens. 2010 May;19(3):260-5

12. Mengel M. Chronische Nierentransplantatschädigung. Warum das CAN-Konzept verlassen werden musste. Der Nephrologe, Vol 5, (4, April), 2010, pp307-313

13. Mengel M. Up-date der Banff-Klassifikation. Der Nephrologe, Vol 5, (6, Juni), 2010, pp494-50014. Liapis H, Koch M, Mengel M. Transplant Pathology of Solid Organ Systems, The Kidney in Pathology

of Solid Organ Transplantation, 1st edition, Chapter 6. edit. by Helen Liapis, Hanlin L. Wan, 2010, pp 77-170

15. Mengel M. Invited Commentary: What Is the Significance of Subclinical Inflammation in Human Renal Allografts? It Depends! Transplantation, 2012; 15;93(1):22-3.

19

M Mengel: CV

16. Mengel M. Diagnostic Pathology: Kidney Diseases edited by Robert B. 2012 Colvin. Am J Transplant. Volume 12, Issue 4, 2012, 1052–1055

17. Mengel M. Transplantation pathology 2013: current diagnostic challenges. (invited editorial) Curr Opin Organ Transplant. 2013 Jun; 18 (3):304-5.

18. Ogbogu U. and Mengel M. Who Owns Diagnostic Specimens in the Era of Personalized Medicine? (invited opinion piece) Canadian Journal of Pathology 2013 Dec; 5 (3): 86-88.

19. Farris AB and Mengel M. Histopathological Syndromes of Graft Rejection and Recurrent Disease: Kidney. Textbook of Organ Transplantation, 1st edition, Section 6, Chapter 81. edit. By Alan D. Kirk, 2014, pp 910-926

20. Mengel M. Renalomics: Molecular Pathology in Kidney Biopsies. Surgical Pathology Clinics 2014, 7, 443–455

21. Nickeleit V., Mengel M., Colvin R. Renal Transplant Pathology. Heptisntall’s Pathology of the Kidney, 7th edition, volume 2, chapter 29. Edit. Charles Jennette, Jean Olson, Fred Silva, Vivette D’Agati, 2014 pp1321-1460

Patents

1. Method for production of Materialblocks with multiple test samplesInventors: R. Lilischkis, R. von Wasielewski, M. MengelGerman Patent DE 10001136 A1 - approvedEuropean Patent No. 1247085 - approvedUS-Patent Nr 35 U.S.C. 154 (b) - approved

2. Methods for monitoring and prognosis of disease course of gastrointestinal tumorsInventors: R. von Wasielewski, M. Mengel, R. Ridder, P. MartinEuropean Patent No. 02002454.3 - approved

20

M Mengel: CV

PRESENTATIONS & SCIENTIFIC MEETINGS

Summary 104 invited speaker presentations at national and international meetings 7 Visiting Professorships and Named Lectureships Ongoing involvement in a variety of national and international scientific meetings as an organizing

committee member, session chair, and abstract reviewer.

Invited Speaker Presentations

1. Annual meeting of the Belgium Society of pathology. 2005. Brussels, Belgium: “Quality control and assurance in immunohistochemical detection of steroid receptors in breast cancer”.

2. University of Mannheim - Department of Nephrology. 2005. Mannheim, Germany: “Nephropathology course Franz Vollhardt - Protocol Biopsies after renal Transplantation”.

3. Roche Pharma - Basic science meeting. 2005. Tutzingen, Germany: “Subclinical inflammation in protocol biopsies from renal transplants”.

4. European Society of Organ Transplantation. 2005. Istanbul, Turkey: “Microchimerism after solid organ Transplantation”

5. 8th Banff Conference on Allograft Pathology. 2005. Edmonton, Canada: “C4d in protocol biopsies from renal allografts”

6. University of Ulm - Department of Nephrology. 2006. Ulm, Germany: “C4d in protocol biopsies”.7. University of Ulm - Department of Transplant-Surgery. 2006. Ulm, Germany: “Morphological

differential diagnosis in renal allograft biopsies”8. University of Mannheim - Department of Nephrology. 2006. Mannheim, Germany:

“Nephropathology course Franz Vollhardt - Protocol Biopsies after renal Transplantation”. 9. Roche Pharma - Basic science meeting. 2006. Tutzingen, Germany: “Patient Management on the

basis of protocol biopsies after renal transplantation”.10. German work group for pancreas transplantation. 2006. Starnberg, Germany: “Pathology of

pancreas allograft biopsies”.11. Nephrology rounds - Community Hospital Offenbach – 2006. Department of Nephrology: “Biopsy

findings in clinically challenging patients”12. Annual meeting of the German society of Nephrology. 2006. Essen, Germany: “Clinico-pathological

Conference”.13. Annual meeting of the Catalan Society of Transplantation. 2007. Barcelona, Spain: “Histology of

progressive renal allograft lesions”.14. University of Mannheim - Department of Nephrology. 2007, Mannheim, Germany:

“Nephropathology course Franz Vollhardt - Protocol Biopsies after renal Transplantation”.15. 9th Banff Conference on Allograft Pathology. 2007. La Corunia, Spain: “Recommendations for

scoring and reporting focal C4d in kidneys” and “Features of protocol biopsies not yet scored in Banff”.

16. Annual meeting of the German Society of Nephrology. 2007. Munich, Germany: “Clinico-pathological rounds – Challenging cases in renal transplantation”.

17. Annual meeting of the German Society of Nephrology. 2007. Munich, Germany: “Histopathology of the progression of chronic allograft loss after kidney transplantation”.

18. University of Mannheim - Department of Nephrology. 2008. Mannheim, Germany: “Nephropathology course Franz Vollhardt - Protocol Biopsies after renal Transplantation”.

19. University of Birmingham, UK – The Timing and Interpretation of Renal Transplant Biopsies – A clinicopathological meeting: 2008. “Interpreting long term changes in renal transplant biopsies”.

21

M Mengel: CV

20. Novartis Scientific Symposia – Protecting the Graft, 2008. Frankfurt, Germany: “Towards improved detection of kidney allograft fibrosis”.

21. Annual meeting of the German society of Nephrology. 2008. Tuebingen, Germany: “Banff 2007 classification – An up-date”.

22. Annual meeting of the American Society of Nephrology. 2008. Philadelphia, USA: “The Transplant Transcriptome: Lessons learned in Rejection and Tolerance”.

23. Annual symposia of the Saxony Society for Nephrology. (Feb. 28. 2009). 2009. Leipzig, Germany: “The Banff classification: An overview for the clinician”.

24. Annual meeting of the United States Canadian Academy for Pathology (USCAP, Mar. 11. 2009). 2009. Boston, USA: “RPS evening case presentation: Acute allograft rejection – your final answer?”

25. University of Mannheim - Department of Nephrology (Mar 14. 2009). 2009. Mannheim, Germany: “Nephropathology course Franz Vollhardt - Protocol Biopsies after renal Transplantation”.

26. World Congress of Nephrology (May 22. – May 25. 2009). 2009. Milan, Italy: “Inflammation in allograft kidneys – what does it mean?”

27. American Transplant Congress (May 30. – June 3.). 2009. Boston, USA: “Histopathological and molecular phenotypes of chronic allograft damage”.

28. 10th Banff Conference on Allograft Pathology (August 9th – 14th, 2009). 2009. Banff, AB Canada: “Significance of the total i-score”.

29. 10th Banff Conference on Allograft Pathology (August 9th – 14th, 2009). 2009. Banff, AB Canada: “Correlating Histopathology to microarray expression data in heart allograft biopsies”.

30. 10th Banff Conference on Allograft Pathology (August 9th – 14th, 2009). 2009. Banff, AB Canada: “Molecular associations of IFTA”.

31. University of Mannheim - Department of Nephrology (Mar 06. 2010). 2010. Mannheim, Germany: “Nephropathology course Franz Vollhardt – “Molecular Analysis of Protocol Biopsies after renal Transplantation”.

32. American Transplant Congress (May 01. – May 05.) 2010. San Diego, USA: “Adding Genotype to Phenotype: Will We Have a Molecular Banff Classification?”.

33. American Transplant Congress (May 01. – May 05.) 2010. San Diego, USA: “Gene Expression: The Technique, Molecules and their Application to Transplantation”.

34. International Society of Nephrology (ISN) Forefront Meeting on Induction and Resolution of Renal Inflammation (May 06. – May 09.). 2010. Sylt, Germany: “Role of B cells in acute and chronic renal allograft rejection”.

35. International Renal Pathology Conference (June 09. – June 12.). 2010. La Coruña, Spain: “Update in Transplant Renal Pathology, Banff 09”.

36. International Renal Pathology Conference (June 09. – June 12.). 2010. La Coruña, Spain: “Clinicopathologic conference – A difficult transplant case”.

37. International Renal Pathology Conference (June 09. – June 12.). 2010. La Coruña, Spain: “Contributions from Molecular and Genomic studies of Transplant Protocol biopsies”.

38. XXIII International Congress of The Transplantation Society (August 15 – 19, 2010). 2010. Vancouver, BC, Canada: “What Should I Know About Acute Rejection and AMR?”.

39. RPS-IPNA-KUFA Renal Pathology course for pediatric nephrologists: From basic concepts to recent advances (August 28 – 29). 2010. New York, NY, USA: “Antibody – Mediated Rejection”.

40. RPS-IPNA-KUFA Renal Pathology course for pediatric nephrologists: From basic concepts to recent advances (August 28 – 29). 2010. New York, NY, USA: “Infections In Allograft Kidney”.

41. Intercongress Meeting of the European Society of Pathology (August 31 – September 4). 2010. Krakow, Poland: “Molecular Transplant Pathology”

42. International Academy of Pathology Meeting (October 10 – October 13). 2010. Sao Paulo, Brazil: “Chronic Allograft Dysfunction and Loss”

22

M Mengel: CV

43. International Academy of Pathology Meeting (October 10 – October 13). 2010. Sao Paulo, Brazil: “Systemspathology in Transplantation”

44. Annual meeting of the Spanish Society of Nephrology (October 17 – October 19) 2010 Granada, Spain: “Molecular correlates in kidney transplants”

45. Annual meeting of the American Society of Nephrology. (November 18. – November 21.) 2010. Denver, USA: “Late Allograft Loss: The Use of Renal Biopsy”

46. Vascular Biology and Transplantation (January 20. - January 22.). 2011. Hannover, Germany: “Inflammation and chronic Rejection”

47. Annual meeting of the United States Canadian Academy for Pathology (USCAP, Feb. 26.). 2011. San Antonio, USA: “RPS Satellite Symposium: Renal Pathology in 2030 – Genomics and Transcriptomics”

48. Annual meeting of the Canadian Society of Transplantation (CST, March 3. – March 6.) 2011, Mont-Tremblant, Canada: “Starting from zero: The value of time-zero allograft biopsies”

49. World Congress of Nephrology (WCN, April 9. – April 12.) 2011, Vancouver, Canada: “Differential Diagnosis of Inflammation in Transplant Biopsies”

50. World Congress of Nephrology (WCN, April 9. – April 12.) 2011, Vancouver, Canada: “Secrets from the transcriptome: molecular risk factors for chronic allograft dysfunction”

51. University of Mannheim - Department of Nephrology (April 16.). 2011. Mannheim, Germany: “Nephropathology course Franz Vollhardt: “Transplantationpathology II – non-rejection, non-infection lesions”.

52. American Transplant Congress (April 30. – May 04.) 2011. Philadelphia, USA: “Histopathological Risk Factors for Renal Allograft Loss”.

53. 11th Banff Conference on Allograft Pathology (June 6th – 10th, 2011). Paris, France: “Progress Report on the C4d BIFQUIT trial”.

54. 11th Banff Conference on Allograft Pathology (June 6th – 10th, 2011). Paris, France: “Chronic Immune Injury in Solid Organ Transplantation”.

55. 11th Banff Conference on Allograft Pathology (June 6th – 10th, 2011). Paris, France: “Improving diagnostics specificity from EMB by biopsy-based gene expression profiling”.

56. 11th Banff Conference on Allograft Pathology (June 6th – 10th, 2011). Paris, France: “The molecular phenotype of six-week protocol biopsies”.

57. 8th ISFA Congress (International Society for Apheresis, September 14th – 17th 2011) Vienna, Austria, Plenary Session presentation:” Antibody-mediated transplant rejection”

58. 15th Congress of the Mexican Transplant Society (September 21th – 24th 2011) Merida, Mexico, Plenary Session presentation: “Which histological & molecular markers better predict outcome in antibody mediated injury and Why?”

59. 15th Congress of the Mexican Transplant Society (September 21th – 24th 2011) Merida, Mexico, Plenary Session presentation: “Molecular diagnostics in renal allograft biopsies: how it will enhance our diagnostic capabilities?

60. 15th Congress of the Mexican Transplant Society (September 21th – 24th 2011) Merida, Mexico: “2011 Banff meeting update”

61. Annual meeting of the American Society of Nephrology. (November 8. – November 12.) 2011. Philadelphia, USA: “Recognition of Chronic Allograft Dysfunction” Course: Kidney Transplantation for the General Nephrologist

62. Somalogics Company research Seminar. (January 5. 2012). Bolder, Co, USA: “Biomarker implementation - the dilemma of not having a true gold standard”

63. Annual meeting of the Canadian Society of Transplantation (CST, February 22. – February 25.) 2012, Quebec City, Canada: “SWOT Analysis of the Banff System”

64. Annual meeting of the Spanish Society of Transplantation (June 23 – June 26) 2012 Madrid, Spain: “Banff up-date in allograft pathology: New concepts in antibody-mediated rejection”

23

M Mengel: CV

65. Annual Meeting of the Mexican Transplant Society (July 26 – July 28 2012) Aguascalientes, Mexico: “2012 up-date on diagnosing antibody-mediated rejection”

66. Annual Meeting of the Mexican Transplant Society (July 26 – July 28 2012) Aguascalientes, Mexico: “Deciphering renal allograft loss”

67. Annual meeting of the American Society of Nephrology. (November 1. – November 4.) 2012. San Diego, USA: “Recognition of Chronic Allograft Dysfunction” Course: Kidney Transplantation for the General Nephrologist

68. Cutting Edge in Transplantation Symposium, American Society in Transplantation (February 14. – February 16.) 2013. Phoenix, Az, USA: “Morphological and Molecular Correlates of Active Antibody-mediated Injury”.

69. Cutting Edge in Transplantation Symposium, American Society in Transplantation (February 14. – February 16.) 2013. Phoenix, Az, USA: “Precision Diagnostics in AMR - What Clinicians Need to Know About”.

70. University of Mannheim - Department of Nephrology (February 23.). 2013. Mannheim, Germany: “Nephropathology course Franz Vollhardt: “Transplantation pathology I – acute and chronic rejection, and post-transplant infection lesions”.

71. University of Mannheim - Department of Nephrology (February 23.). 2013. Mannheim, Germany: “Nephropathology course Franz Vollhardt: “Transplantation pathology II – non-rejection, non-infection lesions”.

72. Annual Scientific Meeting of the Canadian Society of Transplantation. (March 13. – March 16.) 2013. Lake Louise, Canada: “Pathology of AMR- Relevance of C3d, C4d and FCy Staining”.

73. Canadian Association of Pathologists CIQC/CAP-ACP meeting: Quality assurance in diagnostic immunohistochemistry. (April 25. – 26.) 2013. Toronto, Canada: “Update on Class II tests in renal pathology”.

74. Annual meeting of the International Society for Heart and Lung Transplantation (April 25. – 27.) 2013. Montreal, Canada: “Common Pathology findings of Antibody-Mediated Rejection (AMR) across solid organ transplantation”

75. American Transplant Congress. 2013, May18. – May 22. Seattle, USA: ”Making most of allograft biopsy: what every transplant clinician must know”

76. World Congress of Nephrology (WCN, May 31. – June 04.) 2013, Hong Kong, China: “Establishing the diagnosis of antibody-mediated rejection”

77. 12th Banff Conference on Allograft Pathology (August 19th – 23rd, 2013). Comandatuba, Brazil: “BIFQUIT Study Up-date”.

78. 12th Banff Conference on Allograft Pathology (August 19th – 23rd, 2013). Comandatuba, Brazil: “T cell mediated rejection: Insights from molecular studies and implications for treatment”.

79. Annual Meeting of the European Society of Pathology (September 1st – September 4th) 2013. Lisbon, Portugal: “Microvascular inflammation and endothelial cell activation in kidney antibody mediated rejection”

80. Meeting of the European Society of Transplantation (September 8th – September 11th) 2013. Vienna, Austria: “Rejection revisited: Histology was Yesterday”

81. Annual meeting of the Allovir research consortium of the Dutch Kidney Foundation (October 18. – October 19.) 2013: “Molecular and immunopathological correlates of antibody-mediated tissue injury in human renal allografts”

82. Annual meeting of the American Society of Nephrology. (November 5. – November 10.) 2013. Atlanta, USA: “Recognition of Chronic Allograft Dysfunction” Course: Kidney Transplantation for the General Nephrologist

83. Annual meeting of the American Society of Nephrology. (November 5. – November 10.) 2013. Atlanta, USA: Renal Biopsy: Clinical Correlations “A case of C4d-negative antibody-mediated rejection

24

M Mengel: CV

84. Cutting Edge in Transplantation Symposium, American Society in Transplantation (February 13. – February 15.) 2014. Phoenix, Az, USA:” The Detection and Contribution of Organ Senescence to Transplant Survival”

85. Annual meeting of the Canadian Society of Nephrology. (April 24. – April 26.) 2014. Vancouver, Canada: “Clinico-Pathological Conference: A case of C3 glomerulopathy”

86. American Transplant Congress. 2014, July 26. – July 31. San Francisco, USA: Sunrise Symposia, Finding Solutions to Improving Long Term Outcome: “Pathology of Long-term Graft Loss”

87. American Society of Transplantation Fellows Symposium on Transplant Medicine (September 19. – September 21.) 2014 Dallas, Tx, USA: “Histopathologic features of Antibody Mediated Rejection”

88. American Society of Transplantation Fellows Symposium on Transplant Medicine (September 19. – September 21.) 2014 Dallas, Tx, USA: “Overview of the transplant biopsy”

89. European Dialysis and Transplant Renal Association Forefronts in Renal Transplantation CME course (September 27.) 2014, Munich, Germany: “Transplant biopsy beyond light microscopy”

90. Annual meeting of the American Society of Nephrology. (November 13. – November 16.) 2014. Philadelphia, USA: “The unwelcome visitor: De novo DSA”

91. Mayo Clinic Consensus Conference on Glomerulonephritis Classification. (Feb 20.) 2015. “The Banff Perspective”

92. University of Mannheim - Department of Nephrology (February 28.). 2015. Mannheim, Germany: “Nephropathology course Franz Vollhardt: “Transplantation pathology I – acute and chronic rejection, and post-transplant infection lesions”.

93. University of Mannheim - Department of Nephrology (February 28.). 2015. Mannheim, Germany: “Nephropathology course Franz Vollhardt: “Transplantation pathology II – non-rejection, non-infection lesions”.

94. 6th Nephropathology Course, National Institute of Medical Sciences (March 6. – 7.) 2015. Mexico City, Mexico: “Molecular diagnosis and risk assessment of antibody-mediated rejection”

95. 6th Nephropathology Course, National Institute of Medical Sciences (March 6. – 7.) 2015. Mexico City, Mexico: “Up-date on the 2013 Banff revision for antibody-mediated rejection”

96. 6th Nephropathology Course, National Institute of Medical Sciences (March 6. – 7.) 2015. Mexico City, Mexico: “Thrombotic microangiopathy”

97. Annual Meeting International Pediatric Transplant Association (March 28. – March 31.) 2015, San Francisco, USA: “Molecular Diagnostics in Kidney Transplantation”

98. American Society of Transplantation Fellows Symposium on Transplant Medicine (September 25. – September 27.) 2015 Dallas, Tx, USA: “Histopathologic features of Antibody Mediated Rejection”

99. American Society of Transplantation Fellows Symposium on Transplant Medicine (September 25. – September 27.) 2015 Dallas, Tx, USA: “Viral mediated graft pathology”

100. Food and Drug Administration Workshop on Composite End point s on clinical trials (September 28.) 2015 Washington, DC, USA: “Protocol biopsies a review”

101. American Society of Histocompatibility and Immunogenetics, Annual Meeting (September 28. – October 02.) 2015 Savannah, GO, USA: “Diagnosis of Kidney Allograft Rejection – It Takes a Village: The Transplant Pathologist’s Perspective”

102. 13th Banff Conference on Allograft Pathology (October 05. – 10.) 2013. Vancouver, Canada: “Molecular Assessment of ABMR in Heart Transplants”.

103. Canadian Society of Transplantation Annual Scientific Meeting (October 05. – 10.) 2013. Vancouver, Canada: “Antibody Mediated Rejection in Heart Transplantation: What Is The Diagnostic Gold Standard in 2015”

104. The Transplantation Society Webinar (October 20.) 2015: Rejection: T-cell and Antibody-mediated.

25

M Mengel: CV

Visiting Professorships and Named Lectureships1. Nephrology rounds, Department of Nephrology, University of Munich, Germany, February 23. 20072. Nephrology Research Conference, Division of Nephrology, Mount Sinai School of Medicine, New

York, USA, January 22. 20103. Pathology Rounds at University of Washington, Seattle, USA, December 8. 20104. Mayo Clinic Transplantation Grand Rounds, Rochester, USA, January 31. 20115. Benjamin Sturgill Lecture at University of Virginia, USA, May 7. 20136. Visiting Professor and Speaker, Graduate Student Research Day Department of Pathology,

University of Leiden, Netherlands, October 17. 20137. Visiting Professor and Speaker, Zhejiang University, China, June 30. 2015 and China Pharmaceutical

University, Nanjing, China, July 3. 2015

Involvement in National and International Meetings

2002: Organizing Committee Member and Speaker, Satellite Symposia I – Annual Meeting of the German Society of Pathology (DGP):”Gewebearrays – ein neues Instrument der Immunhistochemischen Qualitaetskontrolle” (Tissue microarrays – a new tool for quality control in diagnostic immunohistochemistry)

2005: Faculty, Banff Conference on Allograft Pathology 2006: Member, Abstract Review Committee, Annual Meeting of the German Society of Nephrology:

“Renal and Transplant Pathology” 2006: Chair, Poster Session, Annual Meeting of the German Society of Nephrology: “Renal and

Transplant Pathology” 2006: Member, Organizing Committee, Satellite Symposia – American Transplant Congress

(AST/ASTS): “Protocol biopsies in renal transplantation – insights into patient management and pathogenesis”

2007: Faculty, Banff Conference on Allograft Pathology 2007-2008: Member, Abstract Review Committee, Annual Meeting of the American Society of

Transplantation: “Transplant Pathology” 2008-2009: Co-chair, Abstract Review Committee Annual Meeting of the American Society of Transplantation: “Kidney - Chronic Rejection” 2009: Session Moderator, “Morphological Phenotypoes of chronic renal allograft damage” , Annual

meeting of the American Society of Transplantation. (May 30. – June 3.) Boston, USA 2009: Session Moderator, “Molecular Nephropathology”, Annual meeting of the American Society

of Nephrology (Oct. 29. – Nov. 01.) San Diego, USA 2009: Judge for Oral Presentations, Macgregor Lecture & Research Day, Department of Laboratory

Medicine & Pathology, University of Alberta 2009: Faculty, Banff Conference on Allograft Pathology. 2009-2010: Co-chair, Abstract Review Committee, Annual Meeting of the American Society of

Transplantation: “Kidney - Chronic Rejection” 2010: Session Moderator, Renal Pathology Society Companion Meeting “Endothelial Pathology and

the Kidney” Annual meeting United States Canadian Academy of Pathology (USCAP-meeting Mar 20. – 26.) Washington, DC, USA

2010: Session Moderator, Proffered Paper Section “Kidney Pathology”, Annual meeting United States Canadian Academy of Pathology (USCAP-meeting Mar 20. – 26.) Washington, DC, USA

2010: Session Moderator, “Translational Mechanisms of Chronic Allograft Injury”, Annual meeting of the American Society of Transplantation. (May 01. – May 05.) San Diego, USA

26

M Mengel: CV

2010: Session Moderator, “Pre-Meeting: Essential Immunology for the Clinician: Clinical Applications of Basic Immunology: Part 2”, Annual meeting of the American Society of Transplantation. (May 01. – May 05.) San Diego, USA

2011: Session Moderator Proffered Paper Section, “Kidney Pathology”, Annual meeting United States Canadian Academy of Pathology (USCAP-meeting Feb 26. – March 04.) San Antonio, TX, USA

2011: Session Moderator, “Risk Factors for Renal Allograft Loss” Annual meeting of the American, Society of Transplantation. (April 30. – May 04.) Philadelphia, USA

2011: Session Moderator, “Pathology correlates and Allograft failure”, Annual meeting of the American Society of Transplantation. (April 30. – May 04.) Philadelphia, USA

2011: Abstract Reviewer, 2011 Canadian Cardiovascular Congress 2011: Organizing Committee Member and Faculty, Banff Conference on Allograft Pathology 2011: Abstract Reviewer, 2012 Canadian Society for Transplantation Annual Meeting 2012: Abstract Reviewer, 24th International Congress of the Transplantation Society 2012: Session Moderator, “Clinico-Pathological Conference” Annual meeting of the Canadian

Society of Transplantation. (February 22. – February 25.) Quebec City, Canada 2012: Session Moderator, “Clinico-Pathological Conference” Annual meeting of the American

Society of Transplantation. (June 02. – June 06.) Boston, Canada 2012: Abstract Reviewer, 2012 American Society of Nephrology Annual Meeting 2012: Program and Organizing Committee Member, ‘Cutting Edge of Transplantation’ Symposium of

the American Society of Transplantation 2012: Abstract Reviewer, 2013 Canadian Society for Transplantation Annual Meeting 2013: Session Moderator, “Clinico-Pathological Conference” Annual meeting of the Canadian

Society of Transplantation. (March 13. – March 16.) Lake Louise, Canada 2013: Session Moderator, Renal Pathology Course, Session 4 (Transplantation and tubulointerstitial

diseases) at the World Nephrology Congress (May 31. – June 4.) Hong Kong, China 2013: Webinar Moderator, American Society of Transplantation 2013 webinar series

(http://www.myast.org/T3): “Banff Conference on Allograft Pathology: 2013 Summary” (October 15.)

2013: Faculty, Banff Conference on Allograft Pathology 2013: Session Moderator, “Killer B’s and the latest Buzz about antibody-mediated rejection”,

Annual meeting of the American Society of Nephrology (Nov. 05. – Nov. 10.) Atlanta, USA 2014: Session Moderator, “Next Generation Pathology – In Vivo Imaging” Annual meeting of the

American, Society of Transplantation. (July 26. – July31.) San Francisco, USA 2014: Abstract Reviewer, 2015 American Society of Transplantation Annual Meeting 2014: Session Moderator, “Clinico-Nephrological Conference: Renal Biopsy”, Annual meeting of the

American Society of Nephrology (Nov. 13. – Nov. 16.) Philadelphia, USA 2015: Session Moderator, “Kidney Antibody-mediated Rejection I” Annual meeting of the American

Society of Transplantation. (May 03. – May 06.) Philadelphia, USA 2015: Session Moderator, “Preventive and therapeutic strategies for Antibody-mediated Rejection”

Annual meeting of the European Society of Transplantation. (September 13. – September 16.) Brussels, Belgium

2015: Session Moderator, “Banff Pre-meeting: Precision diagnostics in Transplantation - Molecular pathology”13th Banff Conference on Allograft Pathology (October 05. – 10.) 2013. Vancouver, Canada

2015: Session Moderator, “Joint Plenary Oral Abstract Presentations - Session II” Joint Banff-CST Scientific Meeting October 05. – 10.) 2013. Vancouver, Canada

27

M Mengel: CV

28

M Mengel: CV

RESEARCH FUNDING

Active grants for which I am the principal investigator

Total Amount awarded (CAD)

Duration Grant Agency Project Title

33,000 01/2015 – 06/2016

Astellas Pharma Inc. Canada

Molecular Pathology Applications in Organ Transplantation

750,000 04/2014 – 10/2016

Alberta Innovates and Advanced Education

The Alberta Laboratory for Molecular Diagnostics: A Provincial Facility – Proof of Concept Study

20,000 10/2013 – 12/2015

Bertech Pharma Validation of a immunohistochemical stain for cancer screening on peripheral blood smears

463,000 12/2012 – 03/2016

Leaders Opportunity Fund, Canadian Foundation of Innovation (186,000$) + matching funds by AET and in kind

Translational Pathology Unit

Current active, funded Research for which I am a co-investigator

Total Amount awarded (CAD)

Duration Grant Agency Project Title

35,000 01/2015 – 12/2015

University Hospital Foundation

Molecular diagnostics of antibody-mediated kidney transplant rejection: Diagnostic and Prognostic Biomarker test development for clinical use

45,000 05/2014 – 12/2015

Division of Nephrology, University of Alberta

Molecular diagnostics of antibody-mediated injury in formalin-fixed, paraffin embedded human kidney biopsies

120,000 11/2012 – 04/2016

Roche Organ Transplant Research Foundation

Creation of Swiss Foundation Legal Entity for the Banff Allograft Pathology Classification and Consensus Process (PI – Kim Solez)

5,000,000.00 06/2013 – 05/2018

Alberta Innovates Health Solutions

Metabolomic Devices for Companion Diagnostics and Personalized Medicine (PI – David Wishart)

4,500,000.00 04/2013 – 03/2017

Genome Canada PACE - 'Omics: Personalized, Accessible, Cost-Effective applications of 'Omics technologies (PIs – Christopher McCabe and Tania Bubela)

Past Research Funding

29

M Mengel: CV

Total Amount awarded (CAD)

Duration Role Grant Agency Project Title

75,000 01/2012 – 06/2013

PI Alberta Innovates – Health Solutions

Development of a Business Proposal for a Alberta Centre for Personalized Diagnostics

1,500,000 01/2011 – 06/2012

Co-I Novartis Pharmaceuticals

Developing an expert system for reading the molecular phenotype of biopsies

200,000 01/2010 – 01/2012

PI Roche Organ Transplant Research Foundation

The Integrin-TGF-beta-pathway in Interstitial Fibrosis and Tubular Atrophy in human renal allografts (grant # 701904686)

10,000 01/2011 – 01/2012

PI Organogenesis Inc. Histopathology of artificial skin allografts.

50,000 04/2010 – 05/2011

PI Astellas Pharmaceuticals, Canada

The Banff Working Groups

25,000 01/2010 – 06/2011

PI University of Alberta Hospital Foundation Medical Research Competition

Molecular Phenotyping of Quilty-Lesions in Heart Transplants

90,000 03/2008 – 03/2010

Co-I Astellas Pharmaceuticals

Role of B cells and Plasma cells in the progression of interstitial fibrosis and tubular atrophy in renal allografts

25,000 01/2009 – 12/2009

PI University of Alberta Hospital Foundation Medical Research Competition

Mast Cells in Interstitial Fibrosis and Tubular Atrophy of Renal Allografts

50,000 06/2006 - 10/2008

Co-I Deutsche Forschungsgemeinschaft (=German equivalent of National Institutes of Health)

Recruitment and activation of mesenchymal cells in renal allografts

300,000 03/2005 - 03/2007

PI DFG Project Grant: DFG-ME 2097/3-1

Pathogenetic role of tissue transglutaminase in the development of chronic allograft nephropathy

150,000 06/2003 - 06/2006

PI Brauckmann Wittenberg Heart Foundation

Cardiac in situ microchimerism after heart and bone marrow transplantation

60,000 01/2006 – 12/2006

PI Dr. Werner Jackstaedt Kidney Foundation

Differential and cell-specific gene expression in the mouse model of acute renal failure

60,000 05/2000 - 06/2005

Co-I Provincial Government of Lower Saxony

Patent application grant “Method for production of Materialblocks

30

M Mengel: CV

with multiple test samples”40,000 06/1999 -

06/2000Co-I Research Foundation

Hannover Medical School

Gnotobiotic piglet model for enterohaemorrhagic E. coli associated diseases

40,000 01/2000 - 01/2001

PI Research Foundation Hannover Medical School

Detection of SV40 large T-antigen in neoplasms after renal transplantation

40,000 01/2004 - 01/2005

PI Research Foundation Hannover Medical School

Compartment-specific and quantitative mRNA expression analysis of co-stimulatory molecules in crescentic glomerulonephritis

31

M Mengel: CV

TEACHING & EDUCATIONAL ACTIVITIES

Summary Supervised nephropathology trainees / fellows

- University of Alberta: 11- Hannover Medical School: 3

Supervised undergraduate and graduate students- University of Alberta: 10 (7 as primary supervisor; 3 as co-supervisor)- Hannover Medical School : 8 (as primary supervisor)

Supervised post doctoral fellows- University of Alberta: 3 (as co-supervisor)

Ongoing delivery of training for post- graduates and as part of residency programs Ongoing delivery of training as part of the Royal College of Physicians and Surgeons of Canada

Continuing Professional Development Program and other national and international Continuing Medical Education Programs

Extensive experience with course delivery, design and assessment (Hannover Medical School)

Nephropathology Trainees (postgraduate medical fellows)

Hannover Medical School (Hannover, Germany) 2000: Henning Feist, nephropathology fellow, Institute for Pathology 2002: Magali Marwedel, nephropathology resident, Institute for Pathology 2005: Verena Broecker, nephropathology resident, Institute for Pathology,

University of Alberta (Edmonton, Alberta) 2009: Anil Pant, nephropathology fellow from the University of Katmandu, Nepal 2010: Belinda Lategan, nephropathology fellow from the University of Manitoba, Winnipeg, Canada 2011: Alison Skene, nephropathology and research fellow from the Austin Hospital, Adelaide, South

Australia 2011: Andrea Thiele, nephropathology fellow from the University of Greifswald, Germany 2011: Paula Blanco, nephropathology fellow from the University of Barcelona, Spain 2011/2012: Sufia Husain, nephropathology fellow from the King Fahid Hospital in Ryad, Saudi

Arabia 2012: Mona Anand, nephropathology fellow from New Delhi, India 2012: Aysel Colak from the Ankara Numune Education and Research Hospital, supported by The

Turkish Nephrology Committee 2012: Amani Ahmad Judeh, nephropathology fellow from the King Fahid Hospital in Ryad, Saudi

Arabia 2012: Klouloud Ahmad Saliba, nephropathology fellow from the Institute National de Pathologie,

Lebanon 2013: Seraphin Twagirimana, nephropathology fellow from the General Hospital of Loanatili,

Pointe-Noire, Congo

Undergraduate and Graduate Students

Hannover Medical School (primary supervisor) Imke Müller, Doctoral Thesis: “Prognostic relevance of cytotoxic T-Lymphocytes and of CD40 in

renal transplants with rejection“ 2001-2004

32

M Mengel: CV

Ebru Serinsöz, MD PhD: “Quantitative gene expression analysis in archival renal allograft biopsies after laser microdissection“ 2002-2005

Rena Vrielmann, Doctoral Thesis: “Pathogenetic relevance of onkogenic viruses in epithelial tumors after renal transplantation“ 2002-2005

Ute Mushoff, Doctoral Thesis: “Incidence of C4d in protocol biopsies after renal transplantation“ Fatma Akdere, Doctoral Thesis: “Quantitative expression analysis of co-stimulatory molecules in

sequential cardiac biopsies after heart transplantation“2005-2007 Danny Jonigk, Doctoral Thesis: “Epithelial microchimerism after renal transplantation“ 2000-2005 Robert Bajeski , Doctoral Thesis: “Morphological and immunhistochemical phenotyping of

subclinical infiltrates in protocol biopsies after renal transplantation“ 2004-2006

University of AlbertaPrimary Supervisor

2010: Medgine Mathurin, Summer Student, Undergraduate Student , Project Title: “Molecular phenotyping of Quilty lesions in heart transplants”

2010: Samantha Chan, Summer Student, Undergraduate Student, Project Title: “The Integrin-TGF-β-pathway in Interstitial Fibrosis and Tubular Atrophy in human renal allografts”

2011: Rachel Singer, Summer Student, undergraduate studies, Project Title: “Delineating the Role of B cell in renal allograft rejection”

2011: Samantha Chan, Summer Student, Undergraduate Student, Project Title: “Banff Initiative for Quality Assurance in Transplantation (BIFQUIT)”

2012: Zofia Czarnecka, High-School Student, funded through the 2012 Sanofi BioGENEius Challenge Canada. Project Title: “Characterization of the integrin TGF-β pathway in acute kidney injury

2013: Jeremiah Bolstad: Summer Student, Undergraduate Student, Project Title: “Develoment of a cell based control system for C4d staining”

2014: Bahman Afzali: Medical Student, University Essen German, Thesis research project: “Molecular phenotype of antibody-mediated rejection in heart allografts”

Co-Supervisor 2009-2011: Jeffrey Venner , MSc , Thesis Title: “Role of MCH class I in allograft rejection and delayed

type skin hypersensitivity” 2010: Alisa Scott, Medical Laboratory Service Student, Project Title: “Developing tissue microarray

based on-slide controls for diagnostic immunohistochemistry” 2012-2013: Howard Yan, Medical Student University of British Columbia, recipient of a American

Society of Nephrology (ASN) Student Scholar Grant, Project Title: “Use of Kidney Implantation Biopsy Pathology and Glomerular Size to Predict Changes in Glomerular Function in the recipient after Live Kidney Donation”

2014: Rachel Fung, supervisor for midterm research paper in LMP400/500

Post Doctoral Fellows

University of Alberta, Edmonton (co-supervisor) 2009-2012: Joana Sellares, Project Title: “The molecular prediction of the response to anti-rejection

therapy” 2010 – 2011: Declan De Freitas, Project Title: “Defining the molecular injury response in kidney

allografts” 2014 - : Benjamin Adam, Project Title: “Molecular diagnostics of rejection and tissue injury in

formalin-fixed and paraffin embedded renal allograft biopsies”

33

M Mengel: CV

2014 - : Erin Chapman, Project Title: “Ultrastructural assessment of microcirculation injury in heart allografts with antibody-mediated rejection”

Undergraduate and Graduate Education

Hannover Medical School 1996: Course “Post-mortal examination for medical students” 1996: Course “General histopathology for medical students” 1996: Case presentation “Results of post-mortal examination” 1997: Course “Post-mortal examination for medical students” 1997: Course “General histopathology for medical students” 1997: Case presentation “Results of post-mortal examination” 1998: Course “Post-mortal examination for medical students” 1998: Course “General histopathology for medical students” 1998: Elective course “Introduction in molecular pathology – a lab-experience in molecular genetics,

cytogenetics, and immunohistochemistry” 1998: Elective course “Immunohistochemistry in tumor diagnostics” 1998: Elective course “Immunohistochemistry for the diagnosis of Hodgkin’s disease” 1999: Course “Special histopathology (tumor diagnostics) for medical students” 1999: Elective course “Introduction in molecular pathology – a lab-experience in molecular genetics,

cytogenetics, and immunohistochemistry” 1999: Course “General histopathology for medical students” 2000: Course “Post-mortal examination for medical students” 2000: Course “General histopathology for medical students” 2000: Course “Special histopathology (tumor diagnostics) for medical students” 2000: Elective course “Introduction in molecular pathology – a lab-experience in molecular genetics,

cytogenetics, and immunohistochemistry” 2001: Course “General histopathology for medical students” 2001: Course “Special histopathology (tumor diagnostics) for medical students” 2001: Elective course “Introduction in molecular pathology – a lab-experience in molecular genetics,

cytogenetics, and immunohistochemistry” 2001: Elective course “Immunohistochemistry – from fixation via paraffin embedding to staining” 2002: Course “General histopathology for medical students” 2002: Course “Special histopathology (tumor diagnostics) for medical students” 2002: Elective course “Introduction in molecular pathology – a lab-experience in molecular genetics,

cytogenetics, and immunohistochemistry” 2002: Elective course “Immunohistochemistry – from fixation via paraffin embedding to staining” 2003: Course “Special Pathology – Nephropathology 1 and 2” 2003: Course “General histopathology for medical students” 2003: Oral exams “General Pathology” 2004: Course “Special Pathology – Nephropathology 1 and 2” 2004: Course “General histopathology for medical students” 2004: Oral exams “General Pathology” 2005: Course “Special Pathology – Nephropathology 1 and 2” 2005: Course “General histopathology for medical students” 2005: Oral exams “General Pathology” 2006: Course “General histopathology for medical students” 2006: Oral exams “General Pathology”

34

M Mengel: CV

University of Alberta 2009 Off-service residents training in Anatomical Pathology: “Diagnostic Immunohistochemistry” 2010: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (January

5th, 2010): “Immunohistochemistry in Surgical Pathology” 2010: Off-service residents training in Anatomical Pathology: “Diagnostic Immunohistochemistry” 2010: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (March

16th, 2010): “Renal Pathology: Vascular Disorders” 2010: Medical Students teaching, DMED 514 Renal Section of the Cardiovascular, Pulmonary and

Renal Course, Renal Pathology Computer Laboratory 2010: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (December

14th, 2010): “Transplantation Pathology” 2010: Off-service residents training in Anatomical Pathology: “Diagnostic Immunohistochemistry” 2011: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (March

15th, 2011): “Non-neoplastic kidney pathology: tubulo-interstitial diseases” 2011: Transplant Fellows Lecture Series, University of Alberta (October 03rd, 2011): “Pathology of T

cell mediated rejection” 2011: Off-service residents training in Anatomical Pathology: “Diagnostic Immunohistochemistry” 2012: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (January

31st, 2012): “Transplantation Pathology” 2012: Offsite residents training in Anatomical Pathology: “Diagnostic Immunohistochemistry” 2013: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (January

07st, 2013): “Cardiovascular Pathology” 2013: Transplant Fellows Lecture Series, University of Alberta (January 07th, 2013): “Pathology of T

cell mediated rejection” 2013: Off-service residents training in Anatomical Pathology: “Diagnostic Immunohistochemistry” 2014: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (January

07th, 2014): “Interesting case discussion” 2014: Transplant Fellows Lecture Series, University of Alberta (January 07th, 2014): “Pathology of T

cell mediated rejection” 2014: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (February

04th, 2014): “Interesting case discussion” 2014: Nephrology Fellows Seminar Series, Division of Nephrology, University of Alberta (October 15.

2014): “Introduction into renal Pathology part I – Glomerular diseases” 2014: Nephrology Fellows Seminar Series, Division of Nephrology, University of Alberta (October 22.

2014): “Introduction into renal Pathology part II – Tubulo-interstitial diseases” 2014: Off-service residents training in Anatomical Pathology: “Diagnostic Immunohistochemistry” 2014: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (January

13. 2014): “Transplantation Pathology” 2015: Academic half-day lecture, Division of Anatomical Pathology, University of Alberta (March 3.,

2015): “Interesting case discussion” 2015: Transplant Fellows Lecture Series, University of Alberta (April 21., 2015): “Pathology of T cell

mediated rejection” 2015: Transplant Fellows Lecture Series, University of Alberta (April 28., 2015): “Pathology of the

Donor Biopsy” 2015/2016: Course Coordinator for LMP 400/500 “Introduction into Human Diseases”

o LMP 400/500 Lecture (Sept. 02. 2015): “Introduction”o LMP 400/500 Lecture (Sept. 04. 2015): “Mechanisms of diseases – an Overview”

35

M Mengel: CV

Thesis and Exam Committees 2011: Jeffrey Venner, MSc, Thesis Examination, University of Alberta: “Role of MCH class I in

allograft rejection and delayed type skin hypersensitivity” 2012: Anatomical Pathology Spring Residency (Mock) Examination, University of Alberta 2012: Heather Neufeld, MSc, Thesis Examination, University of Saskatchewan (27.Aug. 2012):

“Application of image analysis in external and internal quality assurance for diagnostic Immunohistochemistry”

2012: Anatomical Pathology Fall Residency (Mock) Examination (12. Sept. 2012), University of Alberta

2013: Aaron Chow, MSc, Thesis Examination, University of Alberta (July 30. 2013): “Development of a mouse model for antibody-mediated rejection after kidney transplantation”

2014: CARMS interviews for Anatomical Pathology residency (January 28th, 2014), University of Alberta

Continuing Medical Education Presentations

Institute of Pathology (Hannover Medical School) 2000: Education and Training Session: “Pathology of Glomerulonephritis” 2003: Education and Training Session: “Urinary bladder pathology.” 2004: Education and Training Session: “Prostatic Intraepithelial Lesions.” 2005: Education and Training Session: “Up-date of the ISHLT classification for heart allograft

rejection.”

Hannover Medical School 2000-2006: Weekly CPC with the Department of Nephrology 2000-2006: Monthly Rounds with the Department of Nephrology: “Nephrologisches Kolloquium” 2002: Grand Rounds: “Peculiar ulcera in the esophagus” Department of Gastroenterology 2003: Grand Rounds: “Nodule at the forearm” Department of Rheumatology 2004: Grand Rounds: “Renal failure after lung transplantation” Department of Nephrology 2005: Grand Rounds: “Skylla and Charybdis – VEGF and FLT-1 at the glomerular basement

membrane” Department of Nephrology 2005: Clinical Nephrology Hannover: “Histopathological Diagnosis at a glance” 2006: Grand Rounds: “Blue organs” Department of Gastroenterology 2006: Grand Rounds: “Whipple after bone marrow transplantation” Department of Haematology 2006: Clinical Nephrology Hannover: “Histopathological Diagnosis at a glance”

University of Alberta Hospital 2007Alberta Transplant Lecture Series: “Scoring Inflammation in Renal Allograft Biopsies”. 2009-Present: Weekly CPC with the Department of Nephrology 2009: Alberta Transplant lecture series (May 20th, 2009): “Abstract presentation for 2009 American

Transplant Congress” 2009: Pediatric Transplant Boot Camp (June 5th, 2009): “What is Rejection? Pathology of Acute

Cellular and Antibody-Mediated Rejection in heart transplants” 2009: Nephrology Grand Rounds (October 23rd, 2009): “An interesting case of glomerular

endothelial injury”

36

M Mengel: CV

2010: Alberta Transplant lecture series (January 13th, 2010): “Antibody-mediated rejection in thoracic transplantation – interesting clinical cases”

2010: Alberta Transplant lecture series (February 3rd, 2010): “Up-date and new insights into the histopathological diagnosis of T cell mediated rejection”

2010: Medical Grand Rounds (February 12th, 2010): “Diagnosing Kidney Allograft Rejection: an example for molecular assessment of tissue biopsies”

2010: Pathology Internal Consult (PIC) Rounds (May 10th, 2010) 2010: Pathology Internal Consult (PIC) Rounds (May 17th, 2010) 2010: Reading Club, Dep't of Computing Science, Alberta Ingenuity Centre for Machine Learning

(October 06th, 2010): “Pathology and Clinic of Obstructive Uropathy” 2010: Nephrology Grand Rounds (October 08th, 2010): “The new Oxford IgA classification” 2011: Alberta Transplant lecture series (February 24th, 2011): “Role of B cells in Renal allograft

rejection – New insights” 2011: Chair - Banff Pathology Course (August 24th – 27th, 2011): “Up-date in gynecological

pathology” 2011: Nephrology Grand Rounds (December 02nd, 2011): “Membranous Nephropathy” 2012 Alberta Transplant Institute lecture series (November 7th, 2012): “How reliable are C4d and BK

as diagnostic markers in renal allograft biopsies – results from the Banff Initiative for Quality Assurance in Transplantation (BIFQUIT)”

2012: Nephrology Grand Rounds (November 30, 2012): “Up-date on Diabetic Nephropathy” 2012: Pulmonology Grand Rounds (December 12, 2012): “Case presentation – Pulmo-renal

syndrome” 2013: Chair - Banff Pathology Course (August 29th – 31st , 2013): “Up-date in genitourinary

pathology” 2014 Alberta Transplant Institute lecture series (January 22nd, 2013): “Up-date from the 2013 Banff

conference” 2014: Professional Development educational lecture to the Human Organ Procurement Exchange

(HOPE) program members (Sept. 09.2014): “Histological assessment of liver and kidney donor biopsies”

2015: Professional Development educational lecture to the Transplant Coordinators and Nurses at the University of Alberta Hospital (May 15. 2015): “How do Pathologists diagnose Rejection”

37

M Mengel: CV

Profession Development Participation in the University of Alberta's Academic Leadership Development program 2011 (Chairs

School, August 31st - September 2nd, 2011) 360°-assessment Faculty of Medicine and Dentistry, Dean’s office (March 2012) Physician Achievement Review (PAR, Royal College of Physicians & Surgeons of Alberta, October

2012) Participation in the University of Alberta's Academic Gold Leadership Development Program:

“Values Based Leadership”(September 2012 – June 2013) Participation in the AHS PMI course “Managing People Effectively Interviewing” (October 27. and

28. 2014) Participation in the AHS PMI course “Conflict Management and Negotiation” (May 28. - 30. 2015)

NON ACADEMIC ACTIVITIES

Founder (in 2000) and CEO of a University spin-off company “multiblock GmbH”, a service company for quality assurance and quality control in diagnostic immunohistochemistry. Exclusive logistics partner for Germany-wide annual quality assurance trials in immunohistochemistry.

2000-2015 llicensing agreement about the patent “Method for production of Materialblocks with multiple test samples” first with Zymed Laboratories then absorbed by Invitrogen Incorporation and now part of Thermo Fischer.

38